Anti-IL-2R alpha therapy in renal transplantation: The promise of steroid-free immunosuppresion. by Meulen, C.G. ter
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/59271
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Anti-IL-2Rα therapy in renal transplantation:  
The promise of steroid-free immunosuppression?  
 
 
 
 
 
Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen 
 
 
 
Proefschrift 
 
 
Ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen op gezag 
van de Rector Magnificus Prof. Dr. C.W.P.M. Blom, volgens besluit van het College van 
Decanen in het openbaar te verdedigen op dinsdag 23 maart 2004, des namiddags om 3.30 uur 
precies 
 
 
door 
 
 
Cornelis Gerrit ter Meulen 
 
Geboren op 9 april 1966 
te Sittard 
Promotor:    Prof. Dr. J.F.M. Wetzels 
 
Co-promotores:   Dr. A.J. Hoitsma 
    Dr. L.B. Hilbrands 
 
Manuscriptcommissie: Prof. Dr. P. Smits 
    Prof. Dr. R.J.M. ten Berge (AMC Amsterdam) 
    Prof. Dr. A.R.M.M. Hermus 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sponsor: Roche pharmaceuticals, Fujisawa Holland B.V., Amgen. 
 
Printing: Printpartners Ipskamp 
 
ISBN:  90-9017721-3 
Contents 
 
Chapter 1 Introduction and outline of the thesis 
Chapter 2 Monoclonal antibodies against the IL-2Rα: Highly effective 
immunosuppression without apparent side effects. 
Chapter 3 Two doses of daclizumab are sufficient for prolonged IL-2Rα 
blockade. 
Chapter 4 Decreased renal excretion of soluble IL-2Rα after treatment with 
daclizumab. 
Chapter 5 The fractional excretion of soluble IL-2Rα is an excellent predictor of 
the IL-2Rα status after treatment with daclizumab. 
Chapter 6 Induction therapy with IL-2Rα blockade can replace corticosteroid 
therapy after renal transplantation. A prospective randomized 
multicenter study. 
Chapter 7 Prevention of accelerated bone loss with a steroid-free 
immunosuppressive regimen and a regimen with four months of 
steroids in the first year after renal transplantation. A prospective 
randomized multicenter study. 
Chapter 8 The influence of corticosteroid therapy on quantitative ultrasound 
parameters of the calcaneus in the first year after renal transplantation. 
Chapter 9 Summary 
Chapter 10 Samenvatting 
Chapter 11 General discussion 
Dankwoord 
Curriculum vitae 
5 
11 
 
23 
 
27 
 
47 
 
63 
 
 
83 
 
 
 
99 
 
119 
125 
131 
149 
151 
 
 Chapter 1 
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In the last two decades the results of renal transplantation have tremendously improved (1). 
With the availability of new and potent immunosuppressive drugs, the incidence of acute 
rejection has decreased to less than 25%; graft survival at one year now ranges from 80 to 
100% (2;3). However, recipients of a renal transplant frequently experience several side 
effects related to the use of the immunosuppressive drugs. Well known adverse effects are an 
increase in cardiovascular risk factors (4) with ensuing cardiovascular morbidity (5), an 
increased susceptibility to infections (6;7) and malignancies (8), an increased bone loss 
leading to bone fractures (9), and a progressive loss of renal function (10). In our endeavor to 
develop optimal immunosuppressive treatment protocols we therefore must weigh the benefits 
of immunosuppression (less rejection episodes, improved graft survival) against the side 
effects. Recently, immunosuppressive agents with a more specific mode of action have 
become available, that offer the prospect of more effective immunosuppression and fewer side 
effects. Examples are basiliximab and daclizumab, monoclonal antibodies against alpha chain 
of the interleukin-2 receptor (IL-2Rα), respectively. 
In this thesis we describe our experience with daclizumab. Specifically, we questioned if the 
use of daclizumab would allow steroid-free immunosuppression.  
In chapter two, the usage of monoclonal antibodies against IL-2Rα in renal transplantation is 
reviewed. In the clinical studies that have been done with daclizumab, the treatment protocols 
required the administration of five i.v. bolus injections of daclizumab at regular intervals after 
transplantation (11;12). However, on theoretical grounds, daclizumab should also be effective 
when used in a lower dose. Therefore we decided to limit the use of daclizumab to two i.v. 
bolus injections administered immediately before and two weeks after transplantation. We 
have evaluated the duration of blockade of the IL-2Rα on peripheral lymphocytes with this 
dosing schedule (chapter three). Measurement of IL-2Rα on peripheral lymphocytes is tedious 
and time-consuming. Therefore, we have looked for an alternative method for monitoring of 
blockade of the IL-2Rα after treatment with daclizumab. Specifically, we have studied the 
urinary excretion of the soluble IL-2Rα during treatment with daclizumab (chapter four). Not 
unexpectedly, we noted that daclizumab decreased the urinary excretion of soluble IL-2Rα, 
probably by binding soluble IL-2Rα, thus forming large complexes that cannot pass the 
glomerular barrier. In chapter five we present data to answer the question if measurement of 
urinary soluble IL-2Rα reflects the blockade of IL-2Rα on peripheral lymphocytes after 
treatment with daclizumab. 
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In the following two chapters we describe the efficacy of daclizumab as a substitute for the 
use of corticosteroids after renal transplantation. In our prospective, multicenter study renal 
transplant recipients were randomized for treatment with either daclizumab (two i.v. bolus 
injections at day 0 and 14) or corticosteroids for four months added to the standard 
immunosuppression with tacrolimus and mycophenolate mofetil. The results of this study are 
described in chapter six (overall results of graft and patient survival, rejection episodes, and 
cardiovascular risk factors) and in chapter seven (specific data on bone mineral density). 
Quantitative ultrasound of bone has been shown to measure the density as well as the 
microarchitecture of bone (13). In a subgroup of patients we have evaluated changes in 
quantitative ultrasound parameters, and compared the results obtained by this technique with 
data on bone mineral density as assessed by dual energy X-ray absorptiometry (chapter 
eight). 
chapter 1   
 8
Outline of the thesis 
The studies described in this thesis provide answers to the following questions: 
1. What is the duration of IL-2Rα blockade after administration of two doses of daclizumab? 
(Chapter 3) 
2. What is the influence of daclizumab on the metabolism of soluble IL-2Rα? (Chapter 4) 
3. Is it possible to predict blockade of IL-2Rα on peripheral lymphocytes after treatment 
with daclizumab by measuring the concentration of soluble IL-2Rα in serum and urine? 
(Chapter 5) 
4. Is steroid-free renal transplantation feasible by using daclizumab in addition to an 
immunosuppressive regimen with tacrolimus and MMF? (Chapter 6) 
5. Are cardiovascular risk factors in the first year after renal transplantation reduced by using 
a steroid-free immunosuppressive regimen? (Chapter 6) 
6. What is the effect of a steroid-free immunosuppressive regimen on bone mineral density 
during the first year after renal transplantation? (Chapter 7) 
7. What is the effect of a steroid-free immunosuppressive regimen on quantitative ultrasound 
parameters during the first year after renal transplantation? (Chapter 8) 
8. Are the changes in bone mineral density as assessed by dual energy X-ray paralleled by 
changes in quantitative ultrasound parameters during the first year after renal transplantation? 
(Chapter 8)
  introduction 
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The results of solid organ transplantation have tremendously improved in the past two 
decades (1). Twenty years ago, when standard immunosuppression consisted of azathioprine 
and prednisone, only 60-65% of the patients had a functioning renal graft at one year after 
transplantation. Acute rejection episodes, occurring in up to 75% of the patients, were an 
important cause of early graft loss. With the use of new and potent immunosuppressive drugs, 
such as the calcineurin inhibitors cyclosporine or tacrolimus, or the antiproliferative drug 
mycophenolate mofetil, the incidence of acute rejection has decreased to less than 25%, and 
graft survival at one year now ranges from 80 to 100% (2;3). 
The T- lymphocyte plays a pivotal role in the process of acute rejection. Therefore, anti T-cell 
antibodies were developed for the prevention, and treatment of acute rejection episodes. 
Polyclonal antibodies against the T-lymphocyte (e.g. antithymocyte globulin (ATG)) were 
generated by immunization of animals (rabbit, horse) with human T-lymphocytes. With the 
use of hybridomas, monoclonal antibodies directed at specific epitopes on the T-lymphocyte 
such as the CD3/T-cell receptor complex (e.g. OKT3) were produced. Both the polyclonal 
and monoclonal antibodies have proved effective for the treatment of acute rejection, however 
at the cost of an increased incidence of opportunistic infections and lymphoproliferative 
diseases (4). Besides, the first administration of these antibodies is frequently complicated by 
a massive release of cytokines, as a result of activation and lysis of T-lymphocytes, leading to 
high fever, arthralgias and capillary leakage. These side effects have limited the use of these 
antibodies, which are reserved for patients at high risk for acute rejection, or for treatment of 
steroid-resistant acute rejection episodes. 
 
Daclizumab and basiliximab 
The balance between immunosuppressive efficacy and adverse events is an important clinical 
problem. Daclizumab and basiliximab, monoclonal antibodies directed against the alpha chain 
of the interleukin 2 receptor (IL-2Rα), seem an important advance by providing highly 
selective immunosuppression without major adverse events. In this article the mechanism of 
action, the pharmacokinetic and -dynamic data, and the results of clinical studies with these 
monoclonal antibodies in renal transplantation are discussed. Finally, we discuss the 
indication for using these monoclonal antibodies, in the perspective of the currently available 
immunosuppressive drugs. 
  monoclonal antibodies against IL-2Rα 
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Mechanism of action 
The interaction between interleukin-2 (IL-2) and the interleukin-2 receptor on the membrane 
of the T-lymphocytes has a central role in the proliferative T-lymphocyte response that 
occurred during acute rejection of a transplanted allograft (5). T-lymphocytes constitutively 
express a receptor with a low affinity for IL-2, consisting of a beta- and a gamma chain. After 
activation of T-lymphocytes, the alpha chain of the interleukin-2 receptor (IL-2Rα) is co-
expressed on their cell membrane. The IL-2Rα associates with the beta- and gamma chain 
and a receptor with a high affinity for IL-2 is formed (Figure 1). Binding of IL-2 to this 
receptor results in a (clonal) proliferation of activated T-lymphocytes, leading to an 
augmentation of the immune response (6). Blockade of the IL-2Rα is known to inhibit the 
proliferation of activated T-lymphocytes. Monoclonal antibodies against IL-2Rα, derived 
from mice, increased the survival of transplanted allografts in several animal studies (7). The 
efficacy of repeated administration of these murine monoclonal antibodies in humans was 
limited due to the formation of neutralizing antibodies (human anti-mouse antibodies, 
HAMA). This problem was overcome by the development of “chimeric” and “humanized” 
antibodies; in this procedure the variable IL-2Rα binding region of the murine antibody is 
combined with the framework of the constant region of a human IgG1 antibody (figure 2). 
These recombinant IL-2Rα antagonists do not lead to the formation of HAMA of clinical 
importance (8;9). Currently, basiliximab (a chimeric antibody) and daclizumab (a humanized 
antibody) have been registered in the Netherlands for prevention of acute rejection after organ 
transplantation. 
 
Pharmacokinetics and –dynamics 
The pharmacokinetic characteristics of daclizumab and basiliximab are comparable to human 
IgG. The plasma half-lives of daclizumab and basiliximab are 11-20 and ±7 days, respectively 
(human IgG1 ±20 days) (9;10). The concentration of the antibodies needed to achieve 
complete blockade of IL-2Rα on the lymphocytes is higher for daclizumab than for 
basiliximab (>0.5-1.0 µg/mL versus >0.2 µg/mL). It is unknown how long blockade of IL-
2Rα should be maintained for optimal rejection prophylaxis. Therefore, the optimal dosing 
regimen is undetermined. Daclizumab has been evaluated in studies using a five-dose regimen 
(1 mg/kg i.v. every 14 days). With this regimen complete IL-2Rα blockade was achieved for 
more than 17 weeks (8). Basiliximab was equally effective when used in a two-dose regimen 
(20 mg i.v. on day 0 and 4), which induced complete IL-2Rα blockade for a shorter period of  
4 to 6 weeks (11). If such a shorter duration of IL-2Rα blockade is equally effective in 
preventing acute rejection episodes, daclizumab might be also effective when administered 
less frequently. The preliminary results of a study in patients who received a kidney and  
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pancreas allograft simultaneously, suggested comparable efficacy of a two and five-dose 
regimen of daclizumab (12). Therefore, blockade of IL-2Rα in the first 4-6 weeks after 
transplantation seems sufficient for adequate rejection prophylaxis. Of note, the number of 
acute rejection episodes did not increase after resolution of the period of IL-2Rα blockade. In 
all studies, acute rejection episodes were observed during complete IL-2Rα blockade (11;13), 
which reflects the potential of cytokines to take over the role of IL-2 as T-cell growth factor 
during IL-2Rα blockade (14). Since both IL-2Rα antagonists closely resemble human IgG1, 
no drug interactions are to be expected. Specifically, both agents have no interaction with 
cyclosporine or mycophenolic acid. 
IL-2 
β 
γ 
α 
β β 
γ γ 
α 
activation 
+ IL-2Rα
antagonist 
1A 1B 1C 
IL-2 
IL-2 
Figure 1. T-lymphocytes constitutively express a receptor with a low affinity for interleukin-2 (IL-
2) on their cellular membrane, consisting of a beta and gamma chain (1A). After activation of T-
lymphocytes, the alpha chain is co-expressed, and in combination with the beta and gamma chain a 
receptor with a high affinity for IL-2 is formed (1B). Binding of IL-2 to the IL-2 receptor results in 
a clonal proliferation of activated T-lymphocytes. Interleukin-2 receptor α antagonists inhibit 
binding of IL-2 to this high affinity receptor (1C), and the clonal proliferation of activated T-
lymphocytes is inhibited. 
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Clinical trials 
In four prospective double-blind placebo controlled trials, the effect of addition of daclizumab 
or basiliximab to a standard immunosuppressive regimen of cyclosporine (CsA) and 
prednisone (with or without azathioprine) was investigated in more than 1200 recipients of a 
renal transplant (10;15-17). The design of these four studies was comparable (Table 1). The 
inclusion to the study was restricted to patients with a low risk for acute rejection (recipients 
of a first allograft, who had no antibodies against HLA). Induction therapy with ATG was not 
used. The patients were followed for one year, and analysis was on an intention-to-treat basis. 
Acute rejection episodes. In all studies the incidence of biopsy-proven acute rejection was 
significantly lower in patients treated with the IL-2Rα antibody (Table 1).  
In the daclizumab treated patients the incidence of acute rejection decreased by 37-40%, in 
the basiliximab treated patients by 29-30%. In all studies, the use of IL-2Rα antibody therapy 
reduced the need for treatment of (steroid-resistant) acute rejection with additional anti-T-
Figure 2. The new generation monoclonal antibodies against the alpha chain of the IL-2 receptor are 
constructed by combination of the variable, IL-2Rα binding region of the original murine antibody 
(A), with the framework and constant regions of a human IgG1 antibody. The chimeric antibody 
basiliximab (B) contains a larger part of the original murine antibody than daclizumab, the humanized 
antibody (C). 
A B C 
=Murine =Humane 
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lymphocyte therapy. The cumulative steroid dose in the first year after transplantation was 
also lower in the IL-2Rα antibody treated group, a logical consequence of the lower rate of 
acute rejection. In two of the four studies, renal function at six months after transplantation 
was better in the IL-2Rα antibody treated patients. 
Survival. Despite the lower rate of acute rejection in the IL-2Rα antibody treated patients, no 
differences were found in one-year graft survival. Only one study reported a 5% improve in 
patient survival (15). 
Side effects It is rather remarkable that in the studies presented so far, the use of daclizumab 
and basiliximab did not lead to an increased number of adverse vents compared with placebo. 
Especially, the cytokine-release syndrome, a common side effect after treatment with OKT-3, 
did not occur. Besides, the incidence of (opportunististic) infections or malignancies (e.g. 
posttransplantation lymphoma) was not increased in any of the four studies. Similar results 
have been obtained in a study evaluating the use of daclizumab after heart transplantation 
(18).
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Discussion 
In conclusion, both daclizumab and basiliximab decrease the incidence of acute rejection after 
renal transplantation, apparently without causing any side effects. The use of IL-2Rα 
antibodies did not improve one-year graft survival. Therefore, studies with long-term follow-
up have to be awaited to determine if the positive effects on preventing acute rejection 
episodes will translate in better long-term survival. Studies comparing daclizumab and 
basiliximab are lacking, and therefore there is no preference for one of the two monoclonal 
antibodies. Using the advised dosing regimen the costs treating an average person of 70 kg are 
± 2.330 Euro’s for basiliximab, and ± 5083 Euro’s for daclizumab. The lower costs together 
with the easiness of the dosing regimen of basiliximab are a clear advantage of this drug. 
However, as stated earlier, it is possible that daclizumab is equally effective in a two-dose 
regimen. In that case, treatment with daclizumab would be somewhat more cost effective.  
Currently, the combination of a calcineurine inhibitor (CsA or tacrolimus), mycophenolate 
mofetil, and prednisone is the standard regimen in most centers in the Netherlands. With this 
combination, the incidence of acute rejection ranges from 15 to 20% (2), lower than the 
rejection rate observed in the presented trials with basiliximab and daclizumab. The 
preliminary results of a phase II double blind randomized trial suggest that the addition of 
daclizumab to CsA, mycophenolate mofetil (MMF) may further decrease the rejection rate to 
±12% (19).  
Acute rejection versus side effects. Although a reduction of the rate of acute rejection may 
seem an important goal of immunosuppressive therapy, the relevance of a low incidence of 
acute rejection for long-term outcome is unclear. Long-term patient and graft survival are 
influenced to a major extent by factors not directly related to acute rejection such as 
cardiovascular disease and malignancies. These factors are dependent on the total 
immunosuppressive load (in case of malignancies), and specific side effects of the 
immunosuppressive drugs. Therefore, the important advance of basiliximab and daclizumab is 
especially the lack of side effects. Current (ongoing) studies address the question whether 
these monoclonal antibodies can safely replace one of the other, more toxic 
immunosuppressive drugs. The preliminary results of a phase II open-label study with a 
calcineurin inhibitor-free immunosuppressive regimen consisting of daclizumab, MMF and 
prednisone revealed an incidence of acute rejection of 50% (20). Thus the replacement of a 
calcineurin inhibitor by an IL-2Rα antibody seems to result in a (unacceptable) high risk for 
acute rejection.  
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At November 1999, a prospective randomized controlled multi-center study was started to test 
the hypothesis that the addition of two doses of daclizumab to tacrolimus and mycophenolate 
mofetil would enable the use of a steroid-free immunosuppressive regimen without affecting 
the incidence of acute rejection. Four kidney transplant centers in the Netherlands are 
participating in this study (Nijmegen, Rotterdam, Utrecht, and Maastricht). The results of this 
study will help to define the position of anti IL-2Rα treatment in transplantation. 
 
Conclusion 
Addition of daclizumab or basiliximab, to a regimen with CsA and prednisone results in a 
decreased incidence of acute rejection in the first year after transplantation, without an 
increase in adverse events. The impact of this finding on long-term graft and patient survival 
is unclear. These agents provide a more selective way of immunosuppression, which might 
allow reducing the dose or avoiding the use of more toxic immunosuppressive drugs.
  20
Reference List 
 1.  Bemelman FJ, Surachno S, ten Berge RJ. Immunology in medical practice. XXX. Organ 
transplantation: indications and results. Ned Tijdschr Geneeskd 2000;144:1432-36. 
 2.  van Gelder T, Gregoor PJ, Hene RJ, De Sevaux RG, Hilbrands LB. Mycophenolic acid: a 
welcome adjunct immunosuppressant after organ transplants. Ned Tijdschr Geneeskd 
1998;142:1550-54. 
 3.  van Oers MH, ten Veen JH. Is cyclosporine a welcome addition in kidney transplantation? Ned 
Tijdschr Geneeskd 1984;128:1058-61. 
 4.  Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative 
disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant 
recipients. N Engl J Med 1990;323:1723-28. 
 5.  Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76. 
 6.  Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2. 
Implications for the level of Tac antigen. J Exp Med 1984;160:1126-46. 
 7.  Reed MH, Shapiro ME, Strom TB et al. Anti-TAC MOAB prolongs renal allografts in 
cynomolgus monkeys. Transplant Proc 1989;21:1028-30. 
 8.  Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in 
renal transplant recipients. Drugs 1999;58:1029-42. 
 9.  Kovarik J, Wolf P, Cisterne JM et al. Disposition of basiliximab, an interleukin-2 receptor 
monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 
1997;64:1701-05. 
 10.  Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to 
prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N 
Engl J Med 1998;338:161-65. 
 11.  Kovarik JM, Kahan BD, Rajagopalan PR et al. Population pharmacokinetics and exposure-
response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal 
Transplant Study Group. Transplantation 1999;68:1288-94. 
 12.  Stratta R, Alloway R, Hodge E. An open-label, comparative trial of two daclizumab dosing 
strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and 
steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients. 
Transplantation 2000;69:S408. 
 13.  Kovarik JM, Moore R, Wolf P et al. Screening for basiliximab exposure-response relationships 
in renal allotransplantation. Clin Transplant 1999;13:32-38. 
 14.  Baan CC, Knoop CJ, van Gelder T et al. Anti-CD25 therapy reveals the redundancy of the 
intragraft cytokine network after clinical heart transplantation. Transplantation 1999;67:870-76. 
 15.  Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection 
by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999;67:110-15. 
  monoclonal antibodies against IL-2Rα 
 21
 16.  Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial 
of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. 
CHIB 201 International Study Group. Lancet 1997;350:1193-98. 
 17.  Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection 
among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor 
monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999;67:276-
84. 
 18.  Beniaminovitz A, Itescu S, Lietz K et al. Prevention of rejection in cardiac transplantation by 
blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 
2000;342:613-19. 
 19.  Vincenti F. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in 
renal transplantation. Transplant Proc 1999;31:2206-07. 
 20.  Vincenti F, Grinyo J, Ramos E et al. Can antibody prophylaxis allow sparing of other 
immunosuppressives? Transplant Proc 1999;31:1246-48.
  22
 
 Chapter 3 
 
 
 
 
Two doses of daclizumab are sufficient for prolonged IL-2Rα blockade 
 
 
 
 
 
CG ter Meulen1, CC Baan2, RJ Hené3, LB Hilbrands1, AJ Hoitsma1. 
Transplantation 2001;72:1709-10. 
 
 
 
1 University Medical Centre Nijmegen, Department of Nephrology 
2 Erasmus Medical Centre Rotterdam, Department of Nephrology 
3 University Medical Centre Utrecht, Department of Nephrology 
chapter 3   
 24
Daclizumab, a humanized antibody to the alpha subunit of the IL-2 receptor (IL-2Rα-chain), 
decreases the incidence of acute rejections after organ transplantation (1;2). After intravenous 
administration the antibody binds to the IL-2Rα-chain of T lymphocytes, thereby inhibiting 
the binding of IL-2 and the subsequent transduction of the IL-2 signal. This results in a 
selective blockade of the activation of antigen-specific T lymphocytes. Blockade of the IL-
2Rα-chain, as measured by flow cytometry, is an in vitro parameter of the effectiveness of 
daclizumab. The current recommendation is to use daclizumab in a regimen consisting of five 
doses of 1 mg/kg intravenously (on day 0 and week 2, 4, 6 and 8 after transplantation). Using 
this regimen in combination with cyclosporine, azathioprine, and prednisone, Vincenti et al. 
(1) observed blockade of the IL-2Rα-chain lasting up to 17 weeks after renal transplantation. 
In a multicenter study, we aimed to block the IL-2Rα-chain for a period of 10 weeks after 
renal transplantation by administration of two doses of daclizumab on day 0 and day 10 after 
transplantation. In case of reappearance of IL-2Rαpos T lymphocytes (as defined by a rise of 
the CD3posCD25pos lymphocytes above 4% of the total population) within the first 10 weeks 
after transplantation, an additional dose of daclizumab was administered. The basic 
immunosuppressive regimen consisted of a combination of tacrolimus and mycophenolate 
mofetil. Flow cytometry was performed in whole blood before the infusion of daclizumab and 
at week 2, 4, 6, 8 and 10 after transplantation in 40 adult recipients of a kidney transplant as 
described previously (3). Reappearance of IL-2Rαpos T lymphocytes was not found in any of 
the patients in the first 10 weeks after transplantation, so no additional doses of daclizumab 
were given. In a subgroup of 24 patients flow cytometry was continued until the IL-2Rαpos T 
lymphocytes reappeared. In these 24 patients IL-2Rαpos T lymphocytes reappeared at 16 
weeks (=median; range 11-30 weeks) following transplantation (figure 1). Five of the 40 
(13%) patients experienced a biopsy-proven acute rejection between 4-81 days after 
transplantation, during a follow-up of 29 weeks (=median; range: 12-48 weeks). Four of these 
rejections appeared during blockade of the IL-2Rα-chain, which underscores the redundancy 
of the immune system in activating T lymphocytes (4). Two of these patients were treated 
with anti-T lymphocyte globulin, because of a steroid resistant acute rejection. There were no 
immunologically mediated graft losses. 
In conclusion, a two-dose regimen of daclizumab in combination with tacrolimus and 
mycophenolate mofetil results in a blockade of the IL-2Rα-chain during more than 10 weeks 
after transplantation. The blockade of the IL-2Rα-chain was longer than expected. This might 
be explained by the co-administration of mycophenolate mofetil, since this drug also 
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increased the duration of the IL-2Rα-chain blockade when co-administered with basiliximab, 
another monoclonal antibody to the IL-2Rα-chain (5). The two-dose regimen of daclizumab 
in combination with tacrolimus and mycophenolate mofetil seems sufficient for adequate 
immunosuppression as is suggested by the low incidence of acute rejection. The benefits of 
the two-dose regimen compared with the previously advocated five-dose regimen are a 
reduction in costs  (saving ± 3000 Euro’s per patient of 75 kg) and the avoidance of the 
logistic problems associated with the intravenous administration of daclizumab in the 
outpatient clinic. 
 
 
 
 
 
 
Figure 1. The moment of reappearance of the IL-2Rαpos lymphocytes after transplantation in 24 
patients who received two doses of daclizumab (1mg/kg/d i.v.).  
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Abstract 
Daclizumab (±150 kD), a humanized mAb against the alpha-chain of the membrane bound 
IL-2 receptor also binds soluble interleukin-2Rα (sIL-2Rα; ±45 kD), and thus may influence 
the glomerular filtration of sIL-2Rα. We have studied the influence of daclizumab on the 
renal excretion of sIL-2Rα in 38 recipients of a renal transplant (32 daclizumab-treated; 6 
controls). Soluble IL-2Rα was measured every two weeks after transplantation in serum and 
urine with Immulite IL-2R, a solid phase ELISA. In the control population the fractional 
excretion of sIL-2Rα was relatively constant with a median value of 1.7±0.5%. In 
daclizumab-treated patients sIL-2Rα was not detectable in the urine immediately after the 
administration of daclizumab. Soluble IL-2Rα became detectable in the urine at a mean of 
8±3 weeks after transplantation. In additional experiments, serum compounds were separated 
by size-exclusion chromatography and sIL-2Rα was measured in the collected fractions. In 
the control patients sIL-2Rα was only present in the low-molecular-weight fractions of serum. 
In contrast, in daclizumab-treated patients evaluated several weeks after transplantation, sIL-
2Rα was merely detected in the high-molecular-weight fractions of serum. During follow-up 
there was a relative shift of sIL-2Rα from the high- to the low-molecular-weight fractions and 
this coincided with normalization of sIL-2Rα excretion. Daclizumab inhibits the renal 
excretion of sIL-2Rα by the formation of a complex with sIL-2Rα in serum, which is too 
large for glomerular filtration. Measurement of urinary sIL-2Rα may provide information on 
the concentration of anti-IL-2Rα mAb in serum.
  soluble IL-2Rα and daclizumab 
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Introduction 
Interleukin-2 (IL-2) plays a critical role in the proliferative expansion of antigen-stimulated T-
cells, and exerts its growth promoting action via specific cell membrane receptors (1). A low 
affinity receptor for IL-2, consisting of a beta and a gamma chain is constitutively expressed 
on lymphocytes. Activation of lymphocytes results in co-expression of the alpha chain (IL-
2Rα or CD25) leading to the formation of an IL-2 receptor with a high affinity for IL-2 (2).  
Soluble interleukin-2 receptor alpha (sIL-2Rα, ±45 kD) is the truncated form of the alpha 
chain of the IL-2 receptor and is derived from proteolytic cleavage of membrane bound IL-
2Rα (3;4). Soluble IL-2Rα retains the ability of binding interleukin-2 with a low affinity (5-
7). Soluble IL-2Rα is found in the urine and serum of healthy persons, and increased serum 
concentrations are found in a variety of diseases such as T-cell leukemia, AIDS, autoimmune 
diseases, and after organ transplantation (3;8). These increased concentrations are the result of 
an increased production and have been proposed to reflect the tumor burden or the rate of 
immunologic activation. In recipients of organ transplants, high concentrations were found 
during acute rejection, CMV infection and after treatment with antithymocyte globulin. 
Several studies have reported that increased concentrations of sIL-2Rα in serum and urine 
may be helpful in detecting acute rejection (9-14), although other studies have challenged the 
usefulness of sIL-2Rα for this purpose (15;16). Normally, 90% of sIL-2Rα is catabolized by 
the kidneys, a process governed by glomerular filtration and tubular reabsorption (17). A 
small amount of filtered sIL-2Rα escapes tubular reabsorption and is excreted in the urine. 
Administration of anti-IL-2Rα antibodies may affect normal renal handling of sIL-2Rα by 
forming a large complex that cannot be filtered. Indeed, administration of anti-IL-2Rα mAb 
in mice appeared to inhibit the renal clearance of sIL-2Rα (17). Thus far, the effect of an anti-
IL-2Rα mAb on the renal excretion of sIL-2Rα has not been studied in humans. Daclizumab, 
a humanized monoclonal IgG1 directed against IL-2Rα is a competitive inhibitor of IL-2 (18). 
Daclizumab has been proven effective for acute rejection prophylaxis after organ 
transplantation, and preliminary results suggest beneficial effects in the treatment of graft-
versus-host disease, uveitis anterior and refractory psoriasis (9;19-22). We investigated the 
influence of daclizumab on the renal excretion of sIL-2Rα in recipients of a renal transplant. 
Our hypothesis was that a decline in the excretion of sIL-2Rα reflects the presence of 
daclizumab in serum. Such a finding might be helpful for therapeutic drug monitoring of 
daclizumab. 
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Materials and methods 
Study population 
The study population consisted of 38 adult patients who received a renal allograft at the 
University Medical Center Nijmegen, the Netherlands. Patients participated in a prospective 
randomized controlled trial comparing induction therapy with daclizumab (1 mg/kg i.v.) on 
day 0 and day 10 after renal transplantation (RTx) with maintenance therapy with prednisone, 
which was tapered from 0.3 mg/kg/day to zero during the first four months after RTx. 
Methylprednisolone 100 mg i.v. was given to all patients during the first three days after RTx. 
The additional standard immunosuppression consisted of tacrolimus and mycophenolate 
mofetil (750 mg bid). Patients receiving daclizumab (N = 32) were compared with prednisone 
treated controls (N = 6).  
 
Analytical methods 
In all patients, peripheral blood and urine samples were collected preoperatively and 
approximately every two weeks during outpatient follow-up visits after RTx. Samples of 
urine produced at 0, 2, 4, and 6 hours after RTx were collected in six recipients of a renal 
transplant with immediate function (controls: N = 3; daclizumab-treated N = 3). Serum was 
frozen at -20 °C and urine at -70 °C until assays were performed in batches. Two urine 
samples that contained more than one gram/L protein were excluded from analysis, to 
preclude that the presence of daclizumab in the urine would interfere with the detection of 
sIL-2Rα in the urine. 
  
ELISA for measurement of sIL-2Rα 
Soluble IL-2Rα was measured with a commercially available automated solid phase, two-site 
chemiluminescent immunometric assay according to the specifications of the manufacturer 
(Immulite; DPC, Los Angeles, CA, USA). This assay employs a murine monoclonal 
antibody against the IL-2Rα (capture antibody) and a polyclonal anti-IL-2Rα-detecting 
antibody. The values are expressed in U/mL based on the reference standard supplied by the 
manufacturer, with limits of detection between 50 and 7200 U/mL.
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Separation of low- versus high-molecular-weight serum fraction 
Serum compounds were separated by size-exclusion chromatography (23) on a hi-load 
Superdex 75 column (prep grade 16/60; Amersham Biosciences, Roosendaal, the 
Netherlands). The Superdex 75 column optimally fractionated serum compounds with a 
molecular weight of ±3 to 70 kD. Serum compounds with a molecular weight above 70 kD 
are not optimally fractionated, and are found in the first elution fractions. We have calibrated 
the column using blue dextran (=V0; ±2000 kD), IgG (±150 kD), albumin (±67 kD), 
ovalbumin (±43 kD), and chymotrypsinogen (±25 kD), dissolved in buffer. Serum samples of 
one mL were diluted two times with buffer (0.05 M KH2PO4, 0.04 M NaOH, and 0.15 M 
NaCl; Ph=7.4), applied to the column, and eluted with the earlier mentioned buffer at a flow-
rate of one mL/min. Elution fractions of one mL were collected. Soluble IL-2Rα was 
measured in all separate fractions in one control patient and compared with the elution pattern 
of a daclizumab-treated patient. In 3 controls and 4 daclizumab-treated patients the respective 
fractions containing substances with an apparent high molecular weight (fraction 49 to 57) 
were combined and fractions containing substances with an apparent low molecular weight 
(fraction 58 to 66) were combined. 
 
Other analysis 
Urine and serum specimens were assayed for creatinine concentrations by automated 
methods. Urinary sIL-2Rα was expressed per millimole of urinary creatinine to correct for 
urine flow and sampling errors. The fractional excretion (FE) of sIL-2Rα was calculated [sIL-
2Rα urine (U/mL) x creatinine serum (µmol/L)] / [sIL-2Rα serum (U/mL) x creatinine urine 
(mmol/L) x 1000] and expressed as percentage. 
 
Statistical analysis 
Unless otherwise indicated, results are expressed as the mean ± SD. A Student t test was 
performed to compare the maximum serum value of sIL-2Rα between groups. A P value less 
than 0.05 was considered statistically significant. The statistical software SPSS version 10.0 
for Windows was used (SPSS, Chicago, IL, USA).
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Results 
The characteristics of the patients are shown in table 1.  In pilot experiments we have 
measured serum sIL-2Rα levels in the morning and in the afternoon to exclude a daytime 
rhythm. No differences were found (989 U/mL versus 988 U/mL; N = 4). Additionally we 
have compared the sIL-2Rα/creatinine ratio in morning urine samples with the sIL-
2Rα/creatinine ratio in 24-hour urine collected at the same day, and again no major difference 
was observed (74 U/mmol versus 75 U/mmol; N = 4). 
 
 
 
Table 1. Patient characteristics and results after transplantation.  
 Controls  
(N = 6) 
Daclizumab-treated 
(N = 32) 
Age (years) 47±14 50±16 
Male (n) 2 20 
LRD/CAD/NHBD (n) 2/3/1 15/12/5 
Acute rejection (n) 0 2 
CMV infection (n) 1 6 
Tacrolimus toxicity (n) 0 3 
Acute tubular necrosis (n) 1 6 
Serum creatininea (µmol/L)  148±54 152±32 
Abbreviations are: LRD, living related donor; CAD, cadaveric donor; NHBD, non-heart beating 
donor; CMV, cytomegalovirus. 
a Three months after transplantation 
 
 
 
Daclizumab influences the measurement of sIL-2Rα by ELISA 
To investigate the effect of daclizumab on the measurement of sIL-2Rα, daclizumab was 
added in concentrations from 0 to 5.0 µg/mL to a control serum. As shown in Figure 1, 
addition of increased doses of daclizumab decreased the levels of sIL-2Rα as measured by the 
Immulite assay. Thus, the ELISA does not allow quantitative measurement of the total 
concentration of sIL-2Rα in serum of daclizumab-treated patients. It remained unclear if the 
ELISA values reflected the concentration of the free sIL-2Rα in serum.
  soluble IL-2Rα and daclizumab 
 33
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Soluble IL-2Rα values in high- and low-molecular-weight fractions of serum 
To determine if the ELISA only detected free sIL-2Rα, additional studies were done using 
size-exclusion chromatography. As expected, in a control patient sIL-2Rα was detected in the 
low-molecular-weight serum fractions (Fig. 2). From Figure 2 it appears that the apparent 
molecular weight of the sIL-2Rα is higher than expected, most likely the result of some 
changes in physiochemical properties of sIL-2Rα in the presence of serum or formation of 
dimers. In this control patient, the sum of sIL-2Rα measured in the different fractions was 
similar to the value measured in unfractionated serum, indicating a good recovery. After 
addition of daclizumab to a control serum (concentration of sIL-2Rα: 1139 U/mL; final 
concentration of daclizumab: 0.9 µg/mL), the measured sIL-2Rα value decreased to 160 
U/mL. After fractionating the serum, sIL-2Rα was only recovered in the serum fractions with 
Figure 1. Adding increased doses of daclizumab interferes with the detection of sIL-2Rα by the 
Immulite assay, probably by competition with the capture antibody of the ELISA for binding sIL-2Rα. 
Soluble IL-2Rα expressed as a percentage of the value at baseline (without daclizumab) in serum 
containing 870 U/mL of sIL-2Rα. *: Limit of detection. 
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a high molecular weight (Fig. 2). The sum of sIL-2Rα measured in the fractions was 
approximately three times higher than the value measured in unfractionated serum, and 
approached the value measured in the serum before the addition of daclizumab.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of dilution on the ELISA measurements 
The difference in sIL-2Rα values measured before and after fractionation of daclizumab-
containing serum might be related to dilution during the fractionation procedure. Therefore, 
the effect of dilution of serum on ELISA measurements was studied in vitro. In control 
patients dilution of the serum did not affect the recovery of sIL-2Rα (i.e. ELISA readings 
decreased linearly to the dilution step) (Fig. 3). In contrast, in daclizumab-treated patients 
Figure 2. Elution pattern of sIL-2Rα in a control patient (open triangles) showing presence of sIL-
2Rα predominantly in the low-molecular-weight serum fractions. After addition of daclizumab (0.9 
µg/mL), sIL-2Rα was only detectable in the fractions with a high molecular weight (closed 
triangles). Soluble IL-2Rα values expressed on log scale; *: Limit of detection = 50 U/mL; 
Calibration of the column was performed with blue dextran (=V0; ±2000 kD), IgG (±150 kD), 
albumin (±67 kD), ovalbumin (±43 kD), and chymotrypsinogen (±25 kD). 
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ELISA readings of diluted serum samples were higher than expected (Fig. 3). Taken together, 
it is evident that in the ELISA the capture antibody competes with daclizumab for binding of 
sIL-2Rα. The amount of sIL-2Rα that is detected by the ELISA therefore depends on the 
concentration and the affinity for sIL-2Rα of both antibodies. This also explains the increase 
in recovery of sIL-2Rα upon dilution of daclizumab containing serum. With increased 
dilution of serum the concentration of daclizumab decreases relative to the (fixed) 
concentration of the capture antibody of the ELISA, and relatively more sIL-2Rα is measured 
by the assay due to an increased dissociation of sIL-2Rα in complex with daclizumab.
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Figure 3. The effect of dilution of serum on the measurement of sIL-2Rα by the ELISA. The values 
are expressed as a percentage of the value without dilution; (open markers: average of three controls; 
black markers: average values of serum taken several weeks after transplantation in two daclizumab-
treated patients). In control patients, dilution of the serum did not affect the recovery of sIL-2Rα, i.e. 
ELISA readings decreased linearly to the dilution step. In contrast, in daclizumab-treated patients 
ELISA readings of diluted serum samples were higher than expected. With increased dilution, the 
concentration of daclizumab decreased relative to the (fixed) concentration of the capture antibody of 
the ELISA, and relatively more sIL-2Rα is measured by the assay due to an increased dissociation of 
the sIL-2Rα-daclizumab complex. 
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The effect of daclizumab on sIL-2Rα values in the urine and serum 
In the control patients the serum concentration of sIL-2Rα decreased in parallel with the 
recovery of renal function after transplantation and remained stable in the absence of an acute 
rejection or CMV infection (Fig. 4A). Soluble IL-2Rα was detectable in the urine collected 
immediately after transplantation (Fig. 5). The fractional excretion of sIL-2Rα was relatively 
constant at an average of 1.7±0.5%.  
There was a characteristic pattern of the measured sIL-2Rα values in the urine and serum in 
all daclizumab-treated patients (Fig. 4A and B), which was completely different from the 
control population. Soluble IL-2Rα was undetectable in the first urine collected immediately 
after the administration of daclizumab (Fig. 5) and urinary sIL-2Rα remained undetectable for 
an average of 8±3 weeks after transplantation. Thereafter the urinary excretion of sIL-2Rα 
increased to values observed in control patients. After the administration of daclizumab the 
serum value of measured sIL-2Rα initially decreased to on average 18±11% of the baseline 
value. Subsequently the measured sIL-2Rα serum value increased to an average maximum of 
130±40% of the baseline value at 15±2 weeks after RTx and subsequently decreased for the 
second time. The peak serum value of sIL-2Rα was approximately two times higher than the 
maximum serum values measured in controls after RTx (P <0.01). The pattern of the serum 
value of sIL-2Rα measured as well as the peak serum value of sIL-2Rα in daclizumab-treated 
patients was not different between patients experiencing (N = 6) or not experiencing (N = 26) 
a CMV infection [average peak serum level of sIL-2Rα: 119±44% versus 133±40% of the 
baseline value (NS)]. 
 
 
Urinary excretion of sIL-2Rα in relation to the presence of sIL-2Rα in different molecular-
weight fractions of serum 
In three control patients, sIL-2Rα was merely detected in the serum fractions with an apparent 
low molecular weight (Table 2). In four daclizumab-treated patients analyzed two weeks 
before the peak serum value of measured sIL-2Rα, sIL-2Rα was predominantly detectable in 
the high-molecular-weight fractions of serum. The urinary sIL-2Rα concentration was low at 
that moment. The sum of the values of sIL-2Rα measured in the high and low molecular 
fractions was up to five times higher than measured in unfractionated serum. This recovery 
was even higher than described in the in vitro experiment of Figure 2 indicating substantial  
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Figure 4A and B. Time course of the mean (±SE) serum (panel A) and urinary (panel B) 
concentration of sIL-2Rα (adjusted for urinary creatinine) in 6 control patients and 32 daclizumab-
treated patients after transplantation. In contrast to the controls, no sIL-2Rα is excreted in 
daclizumab-treated patients in the first weeks after transplantation. 
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accumulation of complexes in these daclizumab-treated patients analyzed several weeks after 
transplantation. 
Subsequent analysis in two daclizumab-treated patients with a nearly normalized fractional 
sIL-2Rα excretion, showed an increase in the proportion of sIL-2Rα measured in the low-
molecular-weight fraction of serum (Table 2). As illustrated in Figure 6, a change of the 
fractional sIL-2Rα excretion towards normal coincides with a relative shift of serum sIL-2Rα 
from the high- to the low-molecular-weight fractions. 
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Figure 5. Urinary excretion of sIL-2Rα in three control patients (open markers) and three patients 
treated with daclizumab (black markers) in the first hours after transplantation. Soluble IL-2Rα was 
undetectable in all three daclizumab-treated patients. 
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Table 2. Soluble IL-2Rα measurements in the high- and low-molecular-weight serum fractions and 
the urinary excretion sIL-2Rα in daclizumab-treated patients and in controls. Values are expressed as 
ranges. 
  Daclizumab-treated (N = 4) 
Measured sIL-2Rα Controls 
(N = 3) 
Before peak 
(N = 4) 
After peaka  
(N = 2) 
Low-molecular-weight fraction (U/mL) 606-1272 0-720 612-787 
High-molecular-weight fraction (U/mL) 0-420 3612-7056 960-1140 
Proportion in low-molecular-weight fraction b 75-100% 0-10% 39-40% 
Urinary concentration (U/mmol creatinine) 73-168 24-51 88-117 
Measured fractional excretion (%) 1.4-2.7 0.3-0.55 1-1.1 
a In daclizumab-treated patients samples were taken before and after the peak of the measured sIL-
2Rα value in serum 
b Expressed as a percentage of the sum of sIL-2Rα recovered in the low- and high-molecular-weight 
fractions
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Figure 6. Elution pattern of sIL-2Rα in a daclizumab-treated patient showing presence of sIL-2Rα 
predominantly in the high-molecular-weight serum fractions (closed circles). The urinary excretion of 
sIL-2Rα at this stage was 28 U/mmol creatinine. This patient was studied six weeks later (open 
circles), when the urinary excretion of sIL-2Rα had increased to 88 U/mmol creatinine (fractional 
excretion 1.0 %). At this time point sIL-2Rα had shifted from the high- to the low-molecular-weight 
fractions of serum. (Soluble IL-2Rα values expressed on log scale; *: Limit of detection = 50 U/mL); 
Calibration of the column was performed with blue dextran (=V0; ±2000 kD), IgG (±150 kD), 
albumin (±67 kD), ovalbumin (±43 kD), and chymotrypsinogen (±25 kD). 
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Discussion 
We have studied the renal handling of sIL-2Rα in renal transplant recipients and specifically 
evaluated the effect of daclizumab.  
Daclizumab is a humanized mAb against the alpha chain of the IL-2 receptor, which is 
expressed on the membrane of activated peripheral lymphocytes. Our data confirm that in 
addition to membrane bound IL-2Rα, daclizumab also binds to the circulating sIL-2Rα. 
Consequently, measurement of circulating sIL-2Rα in daclizumab-treated patients may 
provide information on serum levels of daclizumab. However, the ELISA used for measuring 
sIL-2Rα is not able to provide precise information on either free or total sIL-2Rα levels. The 
detection of sIL-2Rα in the high-molecular-weight fraction and the increased recovery of sIL-
2Rα after dilution of serum of daclizumab-treated patients indicate, that the capture antibody 
of the ELISA and daclizumab compete for binding of sIL-2Rα. Binding of free sIL-2Rα to 
the capture antibody in a serum sample that contains a small amount of sIL-2Rα in 
equilibrium with daclizumab-bound sIL-2Rα will result in some additional dissociation of the 
latter complex. Thus, the measured value of sIL-2Rα will be higher than the original free 
concentration of sIL-2Rα, but substantially lower than the total amount of sIL-2Rα in serum 
since the sIL-2Rα-daclizumab complex will not dissociate completely. Unfortunately there is 
no acceptable alternative for the ELISA to determine the serum concentration of (free) sIL-
2Rα during therapy with daclizumab more accurately. 
On theoretical grounds, we have made the assumption that the detection of sIL-2Rα in the 
urine is not influenced by contamination of the urine with daclizumab. Daclizumab is a 
humanized IgG, and has the same physical properties as IgG (24). The average patient has 50-
100 grams IgG. After the infusion of 150 mg of daclizumab (2x 1 mg/kg body weight), ±0.3% 
of the total IgG content (0.150/ (50 +0.15) x 100%) consists of daclizumab. The average 
concentration of IgG in the urine is 8 mg/L (25). Assuming an intact glomerular barrier, the 
peak concentration of daclizumab in the urine is ±0.3 % x 8 mg/L = 0.02 µg/mL. Considering 
the dose-interference curve of Figure 1, it is unlikely that such a low concentration of 
daclizumab interferes in an important way with the detection of sIL-2Rα in the urine. So 
spilling of daclizumab in the urine with subsequent inhibition of the ELISA is unlikely in the 
absence of a (large) glomerular leak. 
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In the control population, the serum concentration of sIL-2Rα decreased after transplantation 
compared with the value before transplantation, which is probably explained by the recovery 
of renal function leading to the elimination of sIL-2Rα (Fig. 4A) (9;13;15). In accordance to 
others, we found a relatively low fractional excretion of 1.7±0.5%, which suggests tubular 
reabsorption and subsequent catabolism of sIL-2Rα (14).  
In daclizumab-treated patients however, the renal excretion of sIL-2Rα was temporarily 
completely abolished. This effect was noted immediately after the administration of 
daclizumab and lasted up to an average of 8 weeks after RTx. By separating the serum in a 
low- and a high-molecular-weight fraction with size exclusion chromatography, we could 
relate the urinary excretion of sIL-2Rα to the ratio of bound and free sIL-2Rα in the serum at 
different time points. Our results showed that the urinary excretion of sIL-2Rα was low when 
most of sIL-2Rα was bound to daclizumab (= present in the high-molecular-weight fractions), 
whereas the urinary and fractional excretion of sIL-2Rα restored to a normal value in parallel 
with a relative increase of free sIL-2Rα. In other words, formation of a complex of 
daclizumab and sIL-2Rα (sIL-2Rα /anti-IL-2Rα mAb complex: ±200 to 240 kD) that is too 
large for glomerular filtration abrogates the metabolism and urinary excretion of sIL-2Rα 
during therapy of daclizumab. Although the ELISA underestimates total sIL-2Rα levels in 
serum of daclizumab-treated patients, higher values were reached than in controls. This 
increase in the sIL-2Rα values after treatment with daclizumab indicates accumulation of 
complexes of sIL-2Rα and daclizumab. These results confirm the findings of Junghans et al 
who also found a decreased glomerular filtration and subsequently decreased renal catabolism 
in combination with increased serum levels of total sIL-2Rα during anti-IL-2Rα mAb-
directed treatment of mice (17).   
 
Monitoring of sIL-2Rα in the serum or urine seems useless for predicting immunologic 
activation during anti-IL-2Rα-directed mAb therapy. Several patients in our study 
experienced a CMV infection. We could not detect an influence of this stimulus for shedding 
of sIL-2Rα on the pattern of sIL-2Rα values measured in the urine or serum. Apparently, the 
influence of daclizumab on the renal excretion of sIL-2Rα is a more important determinant of 
the sIL-2Rα concentration than the increased shedding of sIL-2Rα associated with a CMV 
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infection. The same might be true for acute rejection, but the proportion of patients 
experiencing an acute rejection was too small for firm conclusions.  
On the other hand, the urinary sIL-2Rα concentration reflects the amount of free sIL-2Rα in 
the serum, which probably is inversely correlated to the concentration of the anti-IL-2Rα 
mAb. Therefore, measuring the urinary excretion of sIL-2Rα may be useful to make sure that 
the concentration of daclizumab is high enough as not to allow detection of sIL-2Rα in the 
urine. The clinical relevance of this finding, however, is unclear and remains to be 
determined. Measurement of sIL-2Rα by an automated ELISA has several advantages above 
the alternative ways of therapeutic drug monitoring of daclizumab like measurement of the 
concentration of daclizumab (26) and flow cytometric analysis of IL-2Rαpos lymphocytes. It 
is easier, can be postponed to another more convenient day, and requires less qualified 
personnel. Prospective studies are needed to compare the methods for the assessment of 
circulating anti-IL-2Rα mAbs. 
 
We expect that these results can be extrapolated to therapy with other mAb directed against 
the IL-2Rα chain. The structure of sIL-2Rα is very similar to that of membrane-bound IL-
2Rα, with similar epitopes (6).  The key factor of the change in catabolism of sIL-2Rα is the 
ability of a mAb to bind sIL-2Rα with subsequent formation of a complex of the mAb and 
sIL-2Rα, which is too large to be filtered by the glomerulus. Preliminary results have shown a 
comparable pattern of the serum concentration of sIL-2Rα after treatment with another IL-
2Rα-blocking mAb, basiliximab (27).  
 
In conclusion, daclizumab inhibited the renal excretion of sIL-2Rα. Measurement of the 
urinary concentration of sIL-2Rα may be useful to make sure that enough anti-IL-2Rα-
directed mAb is present in the circulation to inhibit filtration of sIL-2Rα. The clinical 
relevance of this finding is unclear. Currently, we are comparing the value of monitoring of 
sIl-2Rα in the urine with flow cytometric analysis of IL-2Rαpos lymphocytes after treatment 
with daclizumab in a large cohort of patients. 
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Abstract 
 Daclizumab is a humanized monoclonal antibody against the alpha chain of the IL-2 receptor 
(IL-2Rα). We previously have shown, that the urinary excretion of soluble IL-2Rα (sIL-2Rα) 
is dependent on the presence of daclizumab in serum. We investigated whether the IL-2Rα 
status, as assessed by flow cytometric analysis is reflected by the concentration of sIL-2Rα in 
the urine and serum. 272 measurements were performed in 46 recipients of a renal transplant, 
who were treated with daclizumab in combination with tacrolimus and mycophenolate 
mofetil. Soluble IL-2Rα was measured in urine and serum with Immulite IL-2R, a solid 
phase ELISA. Complete blockade of the IL-2Rα was defined as the presence of less than 5% 
IL-2Rαpos lymphocytes in the CD3pos population. Receiver-Operating Characteristic curve 
(ROC) analysis was done to evaluate the performance of serum and/or urine sIL-2Rα in 
predicting IL-2Rα blockade. The calculated fractional excretion of sIL-2Rα proved to be an 
excellent predictor of the blockade of the IL-2Rα (ROC analysis area under the curve: 
0.95±0.01). A calculated fractional excretion of sIL-2Rα lower than 0.5 percent had a 
specificity of 100 percent and a sensitivity of 75 percent for the assessment of blockade of the 
IL-2Rα. In conclusion, blockade of the IL-2Rα after treatment with daclizumab can reliably 
be assessed by calculation of the fractional excretion of sIL-2Rα. This method is easier to use 
compared with the flow cytometric analysis of IL-2Rαpos lymphocytes.
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Introduction 
Daclizumab, a humanized monoclonal IgG1 directed against the alpha chain of the 
interleukin-2 receptor (IL-2Rα or CD25) is a competitive inhibitor of interleukin-2 (IL-2) (1). 
Daclizumab has been proven effective for acute rejection prophylaxis after organ 
transplantation and preliminary results suggest beneficial effects in the treatment of graft-
versus-host disease, uveitis anterior and refractory psoriasis (2-5). The optimal duration of IL-
2Rα blockade with daclizumab has not been determined yet. Currently, the most widely 
applied method to measure blockade of the IL-2Rα receptor is flow cytometry (2,5-7). 
Measurement of the serum concentration of daclizumab (8) is also informative, but has only 
been performed in highly specialized centers. A serum concentration of daclizumab above 1 
µg/ml was associated with blockade of the IL-2Rα (9). 
Soluble IL-2Rα (sIL-2Rα) is the truncated form of membrane bound IL-2Rα and is released 
by the proteolytic cleavage after activation of lymphocytes (10). Normally 90% of sIL-2Rα is 
catabolized by the kidneys, a process governed by glomerular filtration and tubular 
reabsorption (11). A small amount of filtered sIL-2Rα escapes tubular reabsorption and is 
excreted in the urine. Administration of anti-IL-2Rα antibodies in mice appeared to inhibit the 
renal clearance of sIL-2Rα by forming a large complex that cannot be filtered (11). We have 
confirmed this finding in renal transplant recipients treated with daclizumab (12). After 
treatment with daclizumab the urinary excretion of sIL-2Rα was temporarily completely 
abolished (12). Measurement of the urinary concentration of sIL-2Rα may therefore be useful 
to make sure that enough daclizumab is present in the circulation. A commercial automated 
ELISA is available which allows easy and reliable measurement of sIL-2Rα. We investigated 
whether the level of IL-2Rα blockade as reflected by flow cytometric analysis after treatment 
with daclizumab can be assessed by measuring sIL-2Rα in serum and urine.
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Materials and methods 
Study population 
The study population consisted of 46 adult patients who received a renal allograft at the 
University Medical Center Nijmegen, the Netherlands and were treated with daclizumab [1 
mg/kg intravenously on day 0 and day 10 after renal transplantation (RTx)]. Patients 
participated in a prospective randomized controlled trial comparing induction therapy with 
daclizumab with maintenance therapy with prednisone during the first four months after 
transplantation (13). Thirteen recipients of a renal transplant who were not treated with 
daclizumab were used as controls. All patients received prednisolone 100 mg intravenously 
during the first three days after RTx. The standard maintenance immunosuppression consisted 
of tacrolimus and mycophenolate mofetil (750 mg bid).  
 
Sample collection 
In 30 daclizumab-treated patients and 5 controls peripheral blood and urine samples were 
collected every two weeks during outpatient follow-up visits after RTx. In the other 16 
patients samples were collected at random in the first year after transplantation. Serum was 
frozen at -20 °C, and because of degradation of proteins in urine stored at -20 °C (14), urine 
was frozen at -70 °C.  
 
sIL-2Rα measurement 
Soluble IL-2Rα was measured with a commercially available, automated solid phase, two-site 
chemiluminescent immunometric assay according to the specifications of the manufacturer 
(Immulite; DPC, Los Angeles, CA, USA). Assays were performed in batches within 4 
weeks after sample collection. The average (±SD) recovery of sIL-2Rα in 5 serum samples 
stored at -20 °C for two months, and in 8 urine samples stored for 4 weeks at -70 °C was 
97±7% and 99±13% respectively, so there was no evidence of degradation of sIL-2Rα during 
storage. The assay employs a murine monoclonal antibody against the sIL-2Rα (capture 
antibody) and a second polyclonal anti-IL-2Rα antibody. The values are expressed in U/mL 
based on the reference standard supplied by the manufacturer, with limits of detection 
between 50 and 7200 U/ml. In the presence of daclizumab in the serum, the assay measures 
both free sIL-2Rα, and in part sIL-2Rα in complex with daclizumab (12).
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Flow cytometric analysis 
The presence and expression level of IL-2Rα on lymphocytes was measured in venous blood 
samples, collected in EDTA tubes at the same times as samples for ELISA measurements. All 
procedures were performed at room temperature within 24 hours after collection of blood. 
Whole blood (100 µL) was incubated for 30 minutes in the dark with 5 µL of the mAb anti-
CD45 (clone J.33, Beckman Coulter) conjugated to phycoerythrin-cyanin 5.1 (PC5), 10 µL of 
the mAb anti-CD3 (clone UCHT1, Beckman Coulter) conjugated to fluorescein 
isothiocyanate (FITC), and 20 µL of the mAb anti-CD25 (clone 2A3, Beckton & Dickinson) 
conjugated to phycoerythrin (PE) or as a “negative” control 20 µL of the mAb anti-CD4 
(clone 13B8.2, Beckman Coulter) conjugated to PE. Subsequently, Facs Lysing Solution (2 
ml; Beckton & Dickinson) was added to each sample, mixed well and incubated for 10 
minutes in the dark. Samples were centrifuged for 5 minutes at 1400 RPM in a Sorval RC 3B. 
Cells were washed two times in a phosphate-buffered saline solution (pH 7.4) containing 1% 
BSA and 0.1% sodium azide. Finally the pellet was resuspended in 500 µL phosphate-
buffered saline solution (pH 7.4) containing 1% BSA and 0.1% sodium azide and analyzed on 
a Coulter Epics XL flow cytometer (Beckman Coulter, Miami, FL, USA). 
The lymphocyte population was selected by gating on the side and forward scatter and for 
CD45pos cells (loss of debris). There is no clear separation between the CD3posCD25pos and 
the CD3posCD25neg cells (Figure 1). Therefore, we used the mAb anti-CD4-PE as an isotype 
control to define the cut-off value for CD25-PE pos and CD25-PE neg cells (Figure 1). This cut-
off value was subsequently used to determine the presence and expression level of IL-2Rα on 
lymphocytes. Since the anti-CD25 mAb binds to the same epitope as daclizumab, cells that 
are saturated by daclizumab are not recognized. Complete blockade of the IL-2Rα was 
defined as the presence of less than 5% CD25pos lymphocytes in the CD3pos population.  
 
Other analysis 
Urine and serum specimens were assayed for creatinine concentrations by automated 
methods. Urinary sIL-2Rα was expressed per mmol of urinary creatinine to correct for urine 
flow and sampling errors. The fractional excretion (FE) of sIL-2Rα was calculated by the 
formula: [sIL-2Rα urine (U/mL) x creatinine serum (µmol/L)] / [sIL-2Rα serum (U/mL) x 
creatinine urine (mmol/L) x 1000] and expressed as percentage. 
 
Statistical analyses 
Values are expressed as means ± SD, unless indicated otherwise. Non-parametric tests were 
used to compare values during IL-2Rα blockade with values after disappearance of IL-2Rα  
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blockade in daclizumab-treated patients or with values in controls not treated with 
daclizumab. Receiver-Operating Characteristic curve (ROC) analysis (15) was performed 
with different parameters (urinary sIL-2Rα concentration, and the calculated fractional 
excretion of sIL-2Rα) for the prediction of the IL-2Rα status as assessed with flow cytome-
tric analysis in daclizumab-treated patients only. With ROC analysis the sensitivity and 1-
specificity of the complete spectrum of values of these parameters to predict the IL-2Rα 
status are displayed, and an area under the curve was calculated. A test with a perfect discri-
minative power has a sensitivity and specificity of 100% with an area under the curve of 1. 
 
Figure 1.  Flow cytometric analysis of peripheral blood lymphocytes of a patient before and 28 
days after treatment with daclizumab. The dot plots are gated on lymphocytes. The mAb anti-
CD4-PE was used as an isotype control to define the cut-off value for CD25-PE pos and CD25-PE 
neg cells. Quadrant 4 defining the negative population was set in such a way that gate C contained 
less than 1% of CD4pos cells. Following treatment with daclizumab, the percentage of CD25pos 
cells decreased from 23% to 2% of the CD3pos population in this patient. 
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Results 
Characteristics of the patients are given in Table 1. Two hundred seventy-two measurements 
(190 during and 82 after disappearance of IL-2Rα blockade) were performed in 46 
daclizumab-treated patients (median 7 measurements per patient; range 2-13) and 61 
measurements in 13 controls (median 5 measurements per patient; range 2-12). Serum levels 
of sIL-2Rα showed a typical pattern with a rapid decrease immediately after the first dose of 
daclizumab, followed by a gradual increase (12). Treatment with daclizumab profoundly 
affected the urinary excretion of sIL-2Rα, reflected in a decrease of the urinary excretion of 
sIL-2Rα during IL-2Rα blockade (Figure 2). The urinary excretion of sIL-2Rα normalized as 
soon as plasma daclizumab concentrations had decreased to ineffective levels as indicated by 
the reappearance of CD25pos lymphocytes (Figure 2). ROC analysis based on the complete set 
of measurements in daclizumab-treated patients (Figure 3), indicated that both the urinary 
concentration of sIL-2Rα and the calculated fractional excretion of sIL-2Rα were accurate for 
the assessment of IL-2Rα blockade, with the calculated fractional excretion being somewhat 
better. Limiting the ROC analysis to two measurements per daclizumab-treated patient (one 
measurement during IL-2Rα blockade and one after disappearance of IL2Rα blockade) 
revealed similar but slightly weaker results (AUC for urinary concentration: 0.74±0.06; AUC 
for calculated fractional excretion: 0.93±0.03). Table 2 lists the sensitivities, specificities, and 
positive and negative predictive values for various cut-off values of the two parameters using 
flow cytometric analysis as the gold standard to assess IL-2Rα blockade. Using a value of 
0.5% for the calculated fractional excretion as cut-off for predicting IL-2Rα blockade, the 
specificity was 100% and the sensitivity 75%. Thus, IL-2Rα blockade as assessed by flow 
cytometric analysis was present at all times when the calculated fractional excretion was 
below 0.5% (Table 3). A similar specificity was observed when using 14 U/mmol creatinine 
as cut-off value for the urinary concentration of sIL-2Rα, however the sensitivity was less. In 
a subgroup of 30 daclizumab-treated patients urine and serum samples were collected every 
two weeks after RTx. The duration of IL-2Rα blockade as assessed by flow cytometric 
analysis was 15 weeks (median; range: 10-22 weeks). Six of the subgroup of 30 patients 
(20%) experienced an acute rejection and were treated with methylprednisolone 
intravenously. These rejection episodes were diagnosed at a median of 10 days (range 6-24 
days) after RTx. So all rejection episodes occurred during IL-2Rα blockade. One patient 
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however had a transient increase in the calculated fractional excretion of sIL-2Rα up to 1.8 
percent 11 days after treatment for an acute rejection. No transient increase in the (calculated 
fractional) excretion of sIL-2Rα above the threshold values mentioned was found in patients 
experiencing a CMV infection, tacrolimus toxicity or acute tubular necrosis. 
We estimated the duration of IL-2Rα blockade for two defined cut-off values with exclusion 
of the measurements with a transient increased excretion of sIL-2Rα during the episode of 
acute rejection. Using a cut-off value of 14 U/mmol creatinine for the urinary concentration of 
sIL-2Rα, the blockade of the IL-2Rα was estimated to persist for a median of 9 weeks (range 
3-15 weeks). Using a cut-off value of 0.5 percent for the calculated fractional excretion of 
sIL-2Rα, the duration of the blockade of the IL-2Rα was estimated to persist for a median of 
12 weeks (range: 4-20 weeks). 
 
 
 
 
Table 1. Characteristics of the 46 recipients of a renal transplant treated with daclizumab and 13 
controls, who were not treated with daclizumab. 
 Daclizumab  
(N = 46) 
Control 
(N = 13) 
Age (years) 48±14 48±14 
Male (n; %) 36 (78) 5 (39) 
LRD/CAD/NHBD (n)a 20/20/6 6/5/2 
Acute rejection (n; %) 10 (22) 2 (15) 
Steroid resistant acute rejection (n; %) 2 (4) 0 
CMV infection (n; %) 10 (22) 1 (8) 
Tacrolimus toxicity (n; %) 9 (20) 1 (8) 
Acute tubular necrosis (n; %) 5 (11) 1 (8) 
Serum creatinine a (µmol/L) 147±32 147±49 
Abbreviations are: LRD, living related donor; CAD, cadaveric donor; NHBD, non-heartbeating donor; 
CMV, cytomegalovirus. 
a Three months after transplantation
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Table 2. Sensitivities, specificities, positive and negative predictive values for various cut-off values 
of the urinary concentration of sIL-2Rα and the calculated fractional excretion of sIL-2Rα for 
predicting IL-2Rα blockade after treatment with daclizumab. Flow cytometric analysis was used as the 
gold standard. 
Soluble IL-2Rα  Sensitivity Specificity 
Positive 
predictive 
value 
Negative 
predictive 
value 
Urinary concentration  
(U/mmol creatinine) 
Percentage (95 percent confidence interval) 
< 14 58 (50-65) 100 (96-100) 100 (97-100) 51 (43-59) 
< 35 75 (68-81) 98 (91-100) 99 (95-100) 65 (56-73) 
< 50 81 (74-86)  80 (70-88) 91 (85-95) 64 (54-73) 
 
Calculated fractional excretion 
    
< 0.5% 75 (68-81) 100 (96-100) 100 (97-100) 64 (55-72) 
< 0.6% 85 (79-90) 96 (90-99) 98 (97-100) 73 (64-81) 
< 0.7% 88 (83-93) 95 (88-99) 98 (94-99) 78 (69-86) 
< 0.8% 90 (85-94) 91 (83-96) 96 (92-98) 80 (70-87) 
 
 
 
 
 
 
 
 
Table 3. Actual number of measurements with a calculated fractional excretion of sIL-2Rα lower or 
greater than 0.5 percent in relation to the IL-2Rα status in 46 daclizumab-treated recipients of a renal 
transplant. IL-2Rα blockade as assessed by flow cytometic analysis was present at all times when the 
calculated fractional excretion was below 0.5%. 
 IL-2Rα blockadea ? 
calculated fractional excretion 
of sIl-2Rα <0.5%? 
present 
 
absent 
 
present 143 0 
absent 47 82 
a As assessed by flow cytometric analysis 
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Figure 2. Box plots showing median levels of the urinary sIL-2Rα concentration (Figure 2A) and the 
calculated fractional excretion of sIL-2Rα (Figure 2B) in 46 daclizumab-treated recipients of a renal 
transplant in relation to the IL-2Rα status and in13 controls. Boxes show interquartile (25-75%) 
ranges and error bars represent highest and lowest values. N = number of measurements.  
*P < 0.001 versus after disappearance of blockade and controls (Mann-Whitney test) 
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Figure 3. Receiver-Operating Characteristic Curves for the urinary concentration (Figure 3A) and the 
calculated fractional excretion of sIL-2Rα (Figure 3B) for predicting IL-2Rα blockade after treatment 
with daclizumab using flow cytometric analysis as the gold standard. 
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Discussion 
We have assessed the value of serum and urine sIL-2Rα in predicting complete IL-2Rα 
blockade after treatment with daclizumab. We have prospectively studied 46 recipients of a 
renal transplant who received treatment with daclizumab. The main finding is that both the 
urinary concentration and the calculated fractional excretion of sIL-2Rα are excellent 
predictors of the IL-2Rα status after treatment with daclizumab. 
The excellent performance of these parameters for the prediction of the IL-2Rα status, is 
explained by the fact that both the renal filtration of sIL-2Rα and the blockade of membrane 
bound IL-2Rα depend on the concentration of daclizumab (11,12). Daclizumab temporarily 
inhibits the renal excretion of sIL-2Rα by binding sIL-2Rα, leading to the formation of a 
complex that is too large to be filtered and excreted by the kidney. If the concentration of 
daclizumab decreases, free sIL-2Rα will become present again. Free sIL-2Rα is filtered by 
the glomerulus and subsequently excreted in the urine. These physiological processes explain 
that normalization of the calculated fractional excretion of sIL-2Rα coincides with the 
reappearance of IL-2Rαpos lymphocytes. 
Since the above-mentioned mechanism also applies for other IL-2Rα binding mAbs, it seems 
reasonable to expect that similar results will be found with other IL-2Rα binding mAbs like 
basiliximab. Measurement of sIL-2Rα by an automated ELISA has several advantages 
compared to the alternative ways of therapeutic drug monitoring of daclizumab like 
measurement of the concentration of daclizumab (8) and flow cytometric analysis of IL-
2Rαpos lymphocytes. It is relatively easy, and does not require highly qualified personnel. 
 
It has to be noticed that the ELISA used for measuring sIL-2Rα is not able to provide precise 
information on either free or total sIL-2Rα levels in serum in the presence of daclizumab (12). 
Both the capture antibody of the ELISA and daclizumab compete for binding to sIL-2Rα. 
Binding of free sIL-2Rα to the capture antibody in a serum sample that contains a small 
amount of sIL-2Rα in equilibrium with daclizumab-bound sIL-2Rα will result in some 
additional dissociation of the latter complex. Thus the measured value of sIL-2Rα will be 
higher than the original free concentration of sIL-2Rα but lower than the total amount of sIL-
2Rα in serum since the daclizumab-sIL-2Rα complex does not dissociate completely (12). 
Since the daclizumab-sIL-2Rα complex is too large for glomerular filtration, the ELISA 
measurement in urine samples regards only free sIL-2Rα. 
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The better performance of the calculated fractional excretion of sIL-2Rα compared with the 
urinary concentration for the prediction of the IL-2Rα status is a lucky consequence of the 
overestimation of the serum concentration of free sIL-2Rα by ELISA during the presence of 
daclizumab in serum. This overestimation of the serum levels of free sIL-2Rα, only occurring 
during the presence of daclizumab in the serum, results in a lower value for the calculated 
fractional excretion during IL-2Rα blockade, which enables more accurate classification of 
the IL-2Rα status. In fact, the increase in the measured serum concentration of free sIL-2Rα 
is used as a surrogate marker for the presence of daclizumab. In the calculation of the 
fractional excretion this information is combined with the diminished urinary excretion of 
sIL-2Rα.  
In one of six patients with an acute rejection a transient increase in the calculated fractional 
excretion of sIL-2Rα was seen while the IL-2Rα on lymphocytes was blocked. A decreased 
tubular reabsorption of sIL-2Rα as a consequence of interstitial damage is an attractive 
explanation (16). Anyhow, the calculated fractional excretion of sIL-2Rα seems not reliable 
to determine IL-2Rα blockade during episodes of acute rejection. The knowledge on the IL-
2Rα status at that time however seems less relevant, while acute rejection episodes are treated 
with intensification of the immunosuppressive therapy anyway.  No increase in the 
(fractional) excretion of sIL-2Rα was found in patients experiencing a CMV infection, 
tacrolimus toxicity or acute tubular necrosis. However the number of patients was too low to 
allow firm conclusions on this subject. 
 
The clinical value of monitoring the level and duration of IL-2Rα blockade has still to be 
determined. While therapeutic drug monitoring is not necessary in patients treated with a 
standard dose of anti-IL-2Rα mAb, monitoring might be of value for several reasons. The 
duration of IL-2Rα blockade after a standard dose of basiliximab or daclizumab varies 
considerably (±4-6 weeks for basiliximab (2x 20 mg) versus ±16 weeks for daclizumab (5x 
1mg/kg/week)), while both seem equipotent for the prevention of acute rejection (17). We 
found an unexpectedly long duration of IL-2Rα blockade after two doses of daclizumab (1 
mg/kg) in tacrolimus and MMF treated recipients of a renal transplant (18). Besides 
population characteristics, the concomitant immunosuppressive medication might explain the 
variation in duration of IL-2Rα blockade in these studies (19). Therapeutic drug monitoring 
might be helpful to determine the minimum dose of the (expensive) IL-2Rα blocking mAb 
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required for effective rejection prophylaxis. Furthermore, monitoring might become relevant 
if alternative treatment protocols using anti-IL-2Rα mAbs are developed i.e. prolonged 
treatment in patients with severe toxicity of standard immunosuppressive drugs.  
 
For clinical practice it is important to ensure activity of the agent administered to the patient. 
Therefore we have chosen a cut-off value for the calculated fractional excretion of 0.5 with a 
100 percent specificity and sensitivity of 75 percent, and a cut-off value for the urinary sIL-
2Rα concentration of 14 U/mmol creatinine with a similar specificity but lower sensitivity. 
Using these cut-off values, no patients with recurrence of IL-2Rαpos lymphocytes in the 
circulation were missed. The consequence of a calculated fractional excretion above the 
proposed cut-off values depends on the immunosuppressive protocol. If the protocol requires 
extension of the duration of IL-2Rα blockade, either administration of daclizumab or flow 
cytometric analysis of IL2Rαpos lymphocytes is advised. However, one has to consider that 
the gold standard  (flow cytometric analysis) is not as robust as desired. The cut-off value to 
determine complete IL-2Rα blockade was arbitrarily set at the presence of less than 5% of 
CD25pos lymphocytes in the CD3pos population. So with flow cytometry a low level of IL-2Rα 
expression on lymphocytes was missed. The ELISA already measured sIL-2Rα in the urine in 
the absence of IL-2Rαpos lymphocytes. So the ELISA seems a more sensitive method to 
detect the alpha chain of the IL-2 receptor than flow cytometry. Of course, the exact value of 
determining sIL-2Rα excretion can only be assessed in large clinical studies relating excretion 
of sIL-2Rα with clinical outcome. 
 
In conclusion, blockade of the IL-2Rα after treatment with daclizumab can reliably be 
assessed by measuring the urinary concentration of sIL-2Rα or the calculated fractional 
excretion of sIL-2Rα. These findings can probably be extrapolated to other mAbs against the 
IL-2Rα. For clinical practice this method is easier to use and more sensitive than the flow 
cytometric analysis of IL-2Rαpos lymphocytes. Monitoring of the IL-2Rα status of 
lymphocytes after treatment with daclizumab might be useful for guiding treatment. The cut-
off values reported need to be confirmed in a prospective study. 
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Abstract 
Steroids have been included in most immunosuppressive regimens after renal transplantation, 
but are feared for their side effects. Monoclonal antibodies against the alpha chain of the IL-2 
receptor might give the opportunity to transplant steroid-free. We conducted a prospective, 
randomized, multicenter study to investigate whether this is feasible. A total of 364 patients 
were randomized to receive either daclizumab (1 mg/kg on days 0 and 10 after 
transplantation; steroid-free group N = 186), or steroids (0.3 mg/kg/day tapered to 0 mg at 
week 16 after transplantation; control group N = 178). All patients received tacrolimus, 
mycophenolate mofetil, and for the first three days 100 mg prednisolone intravenously. The 
primary endpoint was the incidence of biopsy-confirmed acute rejection within six months 
after transplantation. Biopsy-confirmed acute rejection was diagnosed in 27 patients in the 
steroid-free group (15%) and in 21 patients in the control group (12%) (95% confidence 
interval of difference: -4 to +10%, NS). Graft survival at 12 months was comparable in the 
two groups (steroid-free group: 91%; control group: 90 %). Mean arterial blood pressure, 
serum lipids, and incidence of patients with hyperglycemia were lower in the steroid-free 
group compared with controls. The immunosuppressive regimen of the steroid-free group was 
associated with increased costs. In conclusion, with the use of anti-IL-2Rα induction therapy 
it is feasible to avoid maintenance therapy with steroids in renal transplant recipients on 
tacrolimus and mycophenolate mofetil.
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Introduction 
Since the early sixties, corticosteroids have been the mainstay for acute rejection prophylaxis 
after organ transplantation. The use of corticosteroids is however associated with several well-
documented side effects as hypertension, hyperlipidemia, new-onset diabetes mellitus, 
infections, accelerated bone loss, weight gain, and cosmetic changes (1). The availability of 
new, potent, and more selective immunosuppressive drugs has challenged the necessity of 
adding corticosteroids for rejection prophylaxis. The introduction of the calcineurin inhibitor 
cyclosporine was a major advance in organ transplantation, positively influencing graft 
survival. Studies concerning withdrawal of steroids in patients on cyclosporine based 
immunosuppressive therapy have shown an improvement in steroid-related side effects (2-5), 
but at the price of an increased incidence in acute rejection (6). Depending on the selection of 
the patients and timing of steroid-withdrawal, up to 50% of the patients had to resume steroids 
(7;8). The calcineurin inhibitor tacrolimus has been shown to be more potent than 
cyclosporine in preventing rejection (9;10). Experience with withdrawal of steroids in patients 
using a tacrolimus based immunosuppressive regimen is limited but promising, although 
steroid-withdrawal related rejection also occurred (11-13). 
Daclizumab is a humanized monoclonal antibody directed against the alpha subunit of the IL-
2 receptor (IL-2Rα-chain) and has been proven effective for rejection prophylaxis after 
transplantation (14;15). Daclizumab is well tolerated, and remarkably, the incidence of 
adverse events is not increased in patients treated with daclizumab. In pilot studies the 
addition of an IL-2Rα blocking antibody to a calcineurin inhibitor combined with 
mycophenolate mofetil, allowed avoidance of corticosteroids (16;17). So far, no randomized 
studies have been published comparing avoidance of steroids with steroid-withdrawal in 
patients on a tacrolimus based immunosuppressive regimen. In a prospective randomized 
controlled multi-center study we tested the hypothesis that the addition of daclizumab to 
tacrolimus and mycophenolate mofetil would preclude the need for corticosteroids without 
affecting the incidence of acute rejection. In the control group prednisone was tapered to zero 
in four months after renal transplantation as the best available alternative to limit the side 
effects of corticosteroids.
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Materials and Methods 
Study design 
We performed a randomized trial at four kidney transplantation centers in the Netherlands. 
Patients were assigned either to treatment with daclizumab (steroid-free group) or to 
maintenance treatment with prednisone during the first four months after transplantation 
(controls). Adult recipients of a first or second transplantation from a living related or 
cadaveric donor were eligible for this study. Excluded were recipients of a graft from an 
HLA-identical living donor, patients taking prednisone or other immunosuppressive 
medications at the time of transplantation, patients with hemolytic uremic syndrome as 
original renal disease, premenopausal women not using adequate contraception, and patients 
with leukocytopenia or thrombocytopenia. 
Shortly before transplantation, patients were randomly assigned to one of the treatment groups 
in an 1:1 ratio, with stratification for cadaveric heart-beating donor/ non-heart-beating donor/ 
living donor, and for center. Randomization was carried out by opening a sealed opaque 
envelope with the lowest available study number at each participating center. Both clinicians 
and patients were aware of the randomized assignment. The protocol was approved by the 
institutional review boards of the four participating hospitals, and written informed consent 
was obtained from all participants before transplantation. 
 
Endpoints 
The primary endpoint was the incidence of a first biopsy-proven acute rejection (Banff type 1 
or higher) within six months after transplantation. Other endpoints included patient and graft 
survival, renal function, incidence of infections, wound dehiscence requiring surgical repair, 
incidence of new-onset diabetes mellitus during the first 12 months after transplantation, and 
blood pressure and lipid values at 2 months and 12 months after transplantation. The change 
in bone mineral density in the first 12 months after transplantation is reported separately (18). 
 
Immunosuppression 
In the steroid-free group, daclizumab (1 mg/kg body weight) was administered intravenously 
one hour before transplantation and once again on day 10-14 after transplantation. We aimed 
to block the IL-2Rα-chain for a period of at least 10 weeks after transplantation. Flow-
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cytometric analysis of IL-2Rαpos lymphocytes as described previously (19), was performed 
biweekly in whole blood. In case of reappearance of IL-2Rαpos lymphocytes (as defined by a 
rise of the CD3posCD25pos lymphocytes above 4% of the total lymphocyte population) within 
the first 10 weeks after transplantation, an additional dose of daclizumab was administered. 
The control population received prednisone 0.3 mg/kg/day orally for the first two weeks, and 
thereafter, the prednisone dose was gradually tapered to zero in four months.  
Concomitant therapy was identical in the two groups. All patients received 100 mg 
prednisolone intravenously during the first three days after transplantation. Induction therapy 
with antilymphocyte therapy was not used. Tacrolimus was started on day one or two after 
transplantation at 0.15 mg/kg twice daily (orally) and the dose was subsequently adjusted to 
achieve target whole-blood trough concentrations of 15-20 ng/ml from day 0-14, 10-15 ng/ml 
from week 3-6, and 5-10 ng/ml after week 7. Tacrolimus concentrations in whole blood were 
measured by the IMx analyzer (Abbott Laboratories, Abbott Park, IL, USA). Mycophenolate 
mofetil (MMF) was administered at 1000 mg twice daily, and decreased to 750 mg twice 
daily at 2 weeks after transplantation, unless the patient weighed more than 90 kg.  
Rejection episodes were primarily treated with methylprednisolone 500-1000 mg 
intravenously for three consecutive days. In case of a steroid-resistant rejection, 
antilymphocyte therapy was given (either rabbit polyclonal antithymocyte globulin or a 
mouse anti-CD3 monoclonal antibody). In case of interruption of tacrolimus or a reduction of 
the MMF dose below 1000 mg/day, or treatment with antilymphocyte therapy, administration 
of prednisone (dose 0.10-0.15 mg/kg/day) was allowed. 
 
Additional medication 
All patients received prophylaxis for peptic ulcers, and Pneumocystis Carinii Pneumonia 
(cotrimoxazole 480 mg daily). Suppletion of elementary calcium (500 mg) and CMV 
prophylaxis was given according to center praxis. 
 
Assessments 
Data on rejection episodes, dialysis requirements, concomitant medication, adverse events, 
and infections were recorded throughout the entire study period. A biopsy was performed in 
cases of deteriorating graft function without an obvious pre- or postrenal cause. No protocol 
biopsies were performed. Biopsies were examined by the local nephropathologist and were 
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classified according to the Banff 1997 Biopsy scoring system (20). For patients who 
underwent several biopsies during a rejection episode, the one with the most severe histologic 
score was recorded. Presumed rejection was defined as treatment with methylprednisolone 
without performing a graft biopsy, or treatment initiated with antirejection therapy while the 
biopsy showed only borderline rejection or no signs of rejection. For calculation of the 
creatinine clearance, the Cockcroft-Gault formula was used (21). Infections were defined as 
any treatment episode with antimicrobial drugs except for the use of prophylaxis. Infections 
were classified using the Centers for Disease Control and Prevention’s definitions for 
nosocomial infections (22).  
 
Statistical Analyses 
Results are given as means ± SD unless stated otherwise. The statistical analyses were 
performed on an intention-to-treat basis. In the primary analysis P-values and 95% confidence 
intervals were calculated using exact methods for the difference of proportions and t-tests for 
the difference of continuous variables. Time to first biopsy confirmed episode of rejection is 
given as Kaplan-Meier curves and compared using the log-rank test. For this analysis, data 
were censored at the time of graft failure due to non-immunological causes, at the time of 
death, at the time of loss to follow-up, or at the end of follow-up. For all tests a P-value less 
than 0.05 (two-sided) was considered significant. 
 
Results 
Between October 1999 and March 2002, 381 patients were enrolled into the study. A total of 
192 patients were assigned to the steroid-free group, and 189 to the control group. Eleven 
patients randomized to the control group and six patients randomized to the steroid-free group 
were excluded from analysis for several reasons, leaving 364 patients for intention-to-treat 
analysis (Figure 1). Two patients in the steroid-free group and one patient in the control group 
were lost to follow-up at six months after transplantation and were excluded from the analysis 
of the endpoints measured at twelve months. The proportion of male patients was higher in 
the steroid-free group compared with the control group. The two groups were not different 
with respect to the other baseline characteristics as shown in Table 1. In the steroid-free group 
28 patients (15%) either had a PRA above 50% or were recipients of a second renal transplant 
as compared to 31 patients in the control group (17%). 
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Table 1. Baseline characteristics of patients and donors. 
Characteristic Steroid-free 
N = 186 
Control 
N = 178 
Median (range) age patients (years) 48 (18-78) 49 (19-73) 
Number of male patients (%) 133 (72) a 102 (57) 
Cause of end-stage renal disease (%)   
Glomerulonephritis 27 24 
Chronic pyelonephritis 13 12 
Polycystic kidney disease 15 19 
Diabetes mellitus 9 7 
Renovascular disease 3 0 
Other  15 19 
Unknown 18 20 
Hemodialysis/peritoneal dialysis /no dialysis 94/69/23 89/73/16 
Median (range) duration of dialysis (months) b 34 (1-250) 32 (1-143) 
Percentage of group with PRA = 0 to 10% /11 to 49% /50 to 100% 80/10/10 74/16/10 
First/second graft (n) 167/19 157/21 
Number of patients (%) with diabetes mellitus before transplantation 23 (12%) 14 (8%) 
Number of patients requiring insulin 21 13 
Cadaveric heart-beating/ non-heart-beating/ living related/ living 
unrelated donor (n) 
72/45/43/26 75/40/37/26 
Median (range) cadaveric donor age (years) 49 (2-75) 49 (14-75) 
Median (range) living donor age (years) 52 (24-77) 50 (21-75) 
Mean HLA-antigen mismatches (n) 2.5±1.3 2.3±1.3 
Mean (SD) cold ischemia time (h) c 20.4±7.6 20.6±6.8 
a P<0.05 between groups. 
b Excluding patients transplanted before renal replacement therapy was started. 
c Cadaveric kidneys only.
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Protocol adherence 
Three of 186 patients (2%) received an extra dose of daclizumab because of recurrence of IL-
2Rαpos lymphocytes in the peripheral circulation within 10 weeks after transplantation. In 55 
of 186 patients (28%) in the steroid-free group initiation of prednisone was judged necessary 
for clinical reasons (42 patients: interruption of other immunosuppressive drug(s), 10 patients: 
rejection, 3 patients: miscellaneous). At twelve months after transplantation 31 of 186 patients 
(17%) in the steroid-free group and 28 of 178 patients (16%) in the control group were still 
treated with prednisone. The median cumulative steroid dose at 12 months after 
transplantation (excluding pulse therapy) was 300 mg per patient (range 300-6800 mg) in the 
steroid-free group and 1607 mg per patient (range 585-5343 mg) in the control group 
(P<0.001). 
Cessation or interruption for more than 14 days of one or more of the immunosuppressive 
drugs was judged necessary for clinical reasons in 39 patients in each group. In the steroid-
free and control group respectively, tacrolimus was discontinued for more than 14 days in 11 
and 10 patients, MMF in 22 and 26 patients, and tacrolimus together with MMF in 6 and 3 
Randomized (n=381) 
Eligible for intention-to-treat analysis (n=186)
Allocated to steroid-free group (n=192) 
Did not receive allocated regimen: 
      •Not transplanted (n=3) 
      •Not meeting inclusion criteria (n=2) 
      •Unknown reason (n=1) 
 
Allocated to control group (n=189) 
Did not receive allocated regimen: 
      •Not transplanted (n=3) 
      •Not meeting inclusion criteria (n=4) 
      •Unknown reason (n=4) 
Eligible for intention-to-treat analysis (n=178) 
Figure 1. Flow diagram of the patients randomized to one of the treatment groups. 
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patients. The reasons for discontinuing of tacrolimus in the steroid-free group and controls 
were nephrotoxicity (6 versus 1), neurotoxicity (1 versus 3), pain of the bones (2 versus 2), 
diabetes mellitus (0 versus 3), and other reasons (8 versus 4). The reasons for discontinuing of 
MMF were gastrointestinal intolerance (12 versus 10), CMV infection (10 versus 6), 
leukocytopenia (3 versus 8), and other reasons (3 versus 5). 
In the steroid-free group tacrolimus trough levels were slightly lower compared with the 
controls at month two (10.2±2.8 versus 11.2±3.9 ng/mL, P<0.01) and six (7.7±2.3 versus 
8.6±2.6 ng/mL, P<0.01) after transplantation. At all other time points there were no 
differences between the two groups in tacrolimus trough levels. 
 
(Biopsy-proven) acute rejection episodes  
The incidence of biopsy-proven acute rejection within the first six months was 15% in the 
steroid-free group and 12% in the control group (NS) (Table 2). The severity of the rejection 
episodes was comparable in the two groups. A type III rejection was observed only once in a 
patient in the control group. All the other acute rejection episodes in the total population were 
classified as type I or II. The time interval to the first biopsy-proven acute rejection was 
comparable in the steroid-free group and the controls: median 11 versus 14 days (range 4-157 
days versus 1-127 days, NS) (Figure 2). No difference between the groups was found in the 
proportion of patients having a presumed rejection, a second biopsy-proven rejection, and the 
proportion of patients treated with antilymphocyte therapy. A biopsy excluded the presence of 
an acute rejection in 13 patients with a presumed rejection in the steroid-free group and in 10 
patients in the control group, and in 4 and 2 patients respectively, a borderline acute rejection 
was found. In the subgroup of patients with either a PRA above 50%, or a second renal 
transplant, 8 of 28 patients (29%) in the steroid-free group experienced a biopsy-proven acute 
rejection as compared to 4 of 31 patients (13%) in the control group (NS).  Multivariate 
analysis including the covariates treatment assignment, center, type of the donor (cadaveric 
heart-beating; non-heart-beating; living), and gender did not change the results. 
 
Patient and graft survival 
At twelve months after transplantation, patient and graft survival were not different between 
the two groups (Table 3). Causes of patient death in the steroid-free group and the controls 
included cardiovascular events (7 versus 3), infections (1 versus 4), lymphoma (1 versus 0) 
and other reasons (0 versus 3). Causes of graft loss were rejection (4 versus 1), vascular 
thrombosis (7 versus 8), primary non-function (4 versus 4), hemolytic uremic syndrome (1 in 
steroid-free group), and infection, bleeding and other causes (2, 1, and 3 in control group).
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Table 2. Rejection episodes during the first 6 months after transplantation. 
 Steroid-free 
N = 186 
Control 
N = 178 
Difference (%) 
(95% CI) a 
Biopsy-proven acute rejection (%) 27 (15) 21 (12) +3 (-4 to +10) 
Type of biopsy-proven acute rejection    
Type I (%) 9 (5) 8 (4) 0 (-4 to +5) 
Type II or III (%) 18 (10) 13 (7) +3 (-3 to +8) 
Biopsy-proven or presumed rejection (%) 54 (29) 38 (21) +8 (-1 to +17) 
Second (biopsy-proven) rejection b (%) 6 (3) 1 (1) +3 (-0 to +5) 
Episode requiring antilymphocyte therapy (%) 11 (6) 4 (2) +4 (-0 to +8) 
a 95% confidence interval of the difference. 
b If a patient had multiple rejection episodes and the episodes occurred within a time interval of 14 
days, the episodes were collapsed and considered as a single event. 
 
 
Figure 2. Kaplan-Meier estimate of the cumulative probability of a biopsy-proven acute rejection 
episode during the first six months after transplantation (steroid-free versus controls: P=0.48).  
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Table 3. Patient and graft survival, incidence of infections, wound dehiscence requiring surgical 
repair, and new-onset diabetes mellitus at 12 months after transplantation. 
 
Steroid-free 
N = 184 
Control 
N = 177 
Difference (%) 
(95% CI) a 
Patient survival (%) 175 (95) 167 (94) +1 (-4 to +5) 
Graft survival (%) 168 (91) 159 (90) +2 (-5 to +8) 
Patients with at least one infection (%) 118 (64) 105 (59) +5 (-5 to +15) 
Patients with wound dehiscence requiring surgical 
repair (%) 
0 (0) 5 (3) -3 (-5 to -0) b 
Patients with new-onset diabetes mellitus (%) 12 (7) 21 (12) -5 (-11 to +1) 
a 95% confidence interval of the difference. 
b P<0.05 
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Figure 3. Mean (±SE) calculated creatinine clearance (*: P< 0.01 between groups). 
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Graft function 
The incidence of delayed graft function, defined as the need for dialysis after transplantation 
was similar in both groups (24% versus 22%, NS). Figure 3 shows that the calculated 
creatinine clearance was slightly lower in the steroid-free group at one month after 
transplantation (45±20 ml/min versus 53±21 ml/min, P<0.01) while no differences were 
found later on (t=12 months: 65±21 ml/min versus 62±21 ml/min). Excluding patients with 
rejection or overt tacrolimus toxicity revealed similar results. The number of patients with 
proteinuria (>1 g/day) was comparable in both groups at 12 months after transplantation (10 
versus 14 patients, NS). 
Episodes of graft dysfunction that resulted in performing a biopsy were more frequent in the 
steroid-free group compared with controls (number of biopsies: 124 versus 85). In 85 of 186 
patients (46%) in the steroid-free group and in 63 of 178 patients (35%) in the control group a 
biopsy was performed (P<0.05). 
 
Incidence of infections, malignancies, and wound dehiscence 
There was no difference between the groups in the proportion of patients that experienced at 
least one infection (Table 3). Also, the number of infections per patient was comparable in 
both groups (1.2±1.4 versus 1.4±1.5 per patient, NS).  
Twelve malignancies were recorded during the 12-month assessment period, six in the 
steroid-free group (carcinomas of bronchus, prostate, skin, mamma, colon, and bladder), and 
two in the control group (carcinomas of prostate and skin). Two patients in each group had a 
post-transplant lymphoproliferative disorder.  
Wound dehiscence requiring surgical repair only occurred in five patients in the control group 
early after transplantation (P<0.05) (Table 3). 
 
New-onset diabetes mellitus, blood pressure and lipids 
During the first 12 months after transplantation new-onset diabetes mellitus, defined as the 
institution of treatment with glucose lowering medication, developed in 12 of 186 patients 
(7%) in the steroid-free group and in 21 of 178 patients (12%) in the control group (NS; Table 
3). Diabetes persisted until the end of follow-up in 11 and 17 patients respectively. Three 
patients, all assigned to the control group, had a transient increase in the serum concentration 
of glucose above 11.1 mmol/L. Although they met the criteria for diagnosing diabetes (23), 
they were never treated with glucose lowering medication. Including the latter patients in the 
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analysis revealed a significantly lower risk to develop diabetes mellitus in the steroid-free 
group (difference with controls: -7% (95% CI: -13 to -1, P<0.05)).  
At 2 months after transplantation mean arterial blood pressure was significantly lower (4 
mmHg, P<0.01) in the steroid-free group compared with the controls, while an equal amount 
of antihypertensive drugs was used (Table 4). At twelve months there was no difference 
between the two groups in mean arterial blood pressure. At two months after transplantation 
mean total cholesterol, high-density lipoprotein cholesterol, and triglycerides were 
significantly lower in the steroid-free group compared with controls (Table 4). At twelve 
months after transplantation these differences had disappeared. A comparable number of 
patients were treated with cholesterol lowering medication at this moment (16 versus 13 
patients, NS). 
 
Costs 
On average 157±40 mg of daclizumab was administered to patients allocated to the steroid-
free group. Based on an actual price of 320 Euro’s/25 mg of daclizumab, the cost of 
daclizumab amounted ±2000 Euro’s per patient in the steroid-free group. The control group 
used a median 1300 mg of prednisone in excess of the steroid-free group. Based on an actual 
price of 0.09 Euro’s/10 mg prednisone, the additional cost of prednisone amounted ±12 
Euro’s per patient in the control group.
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Discussion 
In recipients of a renal transplant who were treated with tacrolimus, MMF, and three days of 
prednisolone, induction therapy with daclizumab without additional steroids resulted in a 
comparable incidence of biopsy-proven acute rejection as continuation of steroids until four 
months after transplantation. This was found despite a clear difference in the cumulative 
steroid dose between the treatment groups. So far, this is the first large prospective 
randomized trial comparing limited exposure to steroids with avoidance of steroids after renal 
transplantation. It clearly shows that daclizumab induction therapy allows renal 
transplantation to be performed successfully with only three days of postoperative 
corticosteroid therapy. More than 80% of the patients in both groups were free from steroid 
treatment at 12 months after transplantation, which is an impressive success rate compared 
with studies concerning steroid-withdrawal in patients on cyclosporine based 
immunosuppressive regimens (7;8). Recipients of a second renal transplant or patients with a 
high PRA accounted for more than 15% of the study population, so the study was not 
restricted to low-risk recipients only. The incidence of biopsy-proven acute rejection in the 
control population (12%) was similar to preliminary reports in patients on tacrolimus and 
MMF based immunosuppression with limited exposure to prednisone (11;24). In both 
treatment arms the majority of the rejection episodes were steroid responsive. Only 15 
patients in the total population (4%) were treated with antilymphocyte therapy for a steroid-
resistant acute rejection, which compares well with large studies on immunosuppression with 
the combination of tacrolimus, MMF and corticosteroids (12;25). A tendency to an increased 
need for antilymphocyte therapy and to an increased incidence in second biopsy-proven acute 
rejection was found in the steroid-free group. The relevance of this finding is unclear. Both 
regimens resulted in similar patient and graft survival rates. At the end of follow-up there was 
no difference in graft function between the two groups. At one month after transplantation, 
graft function was slightly better in patients treated with corticosteroids. This finding was 
independent of the occurrence of a rejection or overt calcineurin inhibitor toxicity as was also 
shown before (26;27), and is possibly explained by a direct hemodynamic effect of steroids on 
glomerular filtration (28). 
 
Traditionally, daclizumab is administered in a five-dose regimen (1 mg/kg every 14 days) 
(14;15). The duration of IL-2Rα blockade required for optimal rejection prophylaxis has not 
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been determined yet, and in recent trials we and others have observed that fewer doses of 
daclizumab may be safe and effective after organ transplantation (29-32). In the present study 
only two doses of daclizumab were administered, and IL-2Rα blockade was maintained 
beyond 10 weeks after transplantation in the vast majority of the patients as was also reported 
earlier (30). In the steroid-free group, 23 of the 27 biopsy-proven acute rejection episodes 
(85%) occurred within the first 10 weeks after transplantation, during IL-2Rα blockade. We 
have shown previously that other cytokines can take over the role of IL-2 as T-cell growth 
factor during IL-2Rα blockade (33). Therefore, we expect no additional effect on acute 
rejection prevention by extending the duration of IL-2Rα blockade with additional doses of 
daclizumab. 
 
Based on the design of the study, differences in steroid-related side effects could especially be 
expected during the first four months after transplantation. In the steroid-free group less 
patients developed diabetes mellitus compared with controls. However, consistent with other 
reports (3;34;35), diabetes mellitus was transient in a proportion of patients after withdrawal 
of steroids. Consequently, a similar percentage of patients remained diabetic in both groups.  
 
At two months after transplantation mean arterial blood pressure was slightly lower in the 
steroid-free group. The total and HDL cholesterol concentrations were lower in the steroid-
free group (on average 9% and 17% respectively). As a consequence, the ratio between total 
and HDL cholesterol, which is known to be a cardiovascular risk factor, did not differ 
between the groups. This finding is in accordance with previously described effects of 
steroids on lipid metabolism after renal transplantation (26;27;36). At twelve months after 
transplantation there were no differences between the two groups in serum lipids and mean 
arterial blood pressure. The meaning of these temporary reductions in the frequency of 
diabetes mellitus and in blood pressure is unclear, but it might be of benefit in those patients 
at high cardiovascular risk (37). 
 
No difference between the groups was found in the incidence of infections, possibly due to 
the systematic use of antiviral and antimicrobial prophylaxis. Finally, there was a significantly 
increased incidence of wound dehiscence requiring surgical repair in the group with limited 
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steroid exposure. Although steroid use is related with wound dehiscence after surgery (38), 
the numbers in our study are small and these results should therefore be interpreted with 
caution. 
 
A global cost analysis shows that the steroid-free regimen was more expensive than the 
regimen with limited steroid-exposure. Besides the increased need to perform a renal biopsy 
and the tendency to increased usage of ATG in the steroid-free group, induction therapy with 
two doses of daclizumab was more costly than four months corticosteroid therapy. 
 
Inherent to its design our study also has some limitations. The so-called steroid-free regimen 
was not completely steroid-free as patients received prednisolone for the first three days after 
transplantation. The influence of three days of 100 mg prednisolone intravenously on 
parameters such as glucose metabolism and infections is unknown. Furthermore we have not 
proven that treatment with daclizumab is really necessary to achieve the results that were 
obtained in our steroid-free group. This would have required an additional study group, only 
treated with tacrolimus and MMF.  
 
In conclusion, treatment with two doses of daclizumab enabled a steroid-free 
immunosuppressive regimen of tacrolimus and mycophenolate mofetil in recipients of a renal 
transplant. There was no difference in the incidence of biopsy-proven acute rejection 
compared with a regimen with limited steroid exposure. Our results indicate a beneficial 
effect on the cardiovascular risk profile of renal transplant recipients treated with a steroid-
free immunosuppressive regimen. This beneficial effect should be balanced against the 
increased costs associated with the steroid-free regimen. 
 
 
Acknowledgements 
The results of this study were presented in part at the 2nd international congress on 
immunosuppression, December 2001, San Diego, and the 22nd annual meeting of the ASTP, May 
2002, Washington. The authors thank M. van Helden, research nurse, for invaluable help in collecting 
the data. The study was financially supported by unrestricted grants of Roche Pharmaceuticals, 
Mijdrecht, and Fujisawa, Houten, the Netherlands.
chapter 6   
 80
Reference List 
 1.  Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of 
steroid-related side effects after renal transplantation. Am J Kidney Dis 1999;33:829-39. 
 2.  Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison 
of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of 
acute renal allograft rejection. Transplantation 2000;70:1352-59. 
 3.  Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on 
posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. 
Transplantation 1991;51:374-77. 
 4.  Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on 
cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal 
Study Group. Transplantation 1999;68:1865-74. 
 5.  Smak Gregoor PJ, De Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or 
prednisone six months after kidney transplantation in patients on triple drug therapy: a 
randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365-73. 
 6.  Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression 
withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11:1910-17. 
 7.  Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal 
in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 
1997;8:294-301. 
 8.  Ponticelli C, Tarantino A, Segoloni GP et al. A randomized study comparing three 
cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group 
for Renal Transplantation (SIMTRe). J Am Soc Nephrol 1997;8:638-46. 
 9.  Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal 
transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-07. 
 10.  Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in 
renal transplantation: a randomised multicentre study. Lancet 2002;359:741-46. 
 11.  Squifflet JP, Vanrenterghem Y, Van Hooff JP, Salmela K, Rigotti P. Safe withdrawal of 
corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, 
randomized study. Transplant Proc 2002;34:1584-86. 
 12.  Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial of 
tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant 
recipients. Transplantation 1999;67:411-15. 
 13.  Boots JM, Christiaans MH, Van Duijnhoven EM, Van Suylen RJ, Van Hooff JP. Early steroid 
withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 
2002;74:1703-09. 
  steroid-free immunosuppression and rejection 
 81
 14.  Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection 
by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999;67:110-15. 
 15.  Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to 
prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N 
Engl J Med 1998;338:161-65. 
 16.  Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete 
steroid avoidance immunosuppression protocol in pediatric renal transplantation. 
Transplantation 2001;72:13-21. 
 17.  Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the 
prevention of acute rejection in renal allograft recipients. Transplantation 2001;72:845-50. 
 18.  ter Meulen CG, van Riemsdijk IC, Hene RJ et al. Prevention of accelerated bone loss with a 
steroid-free immunosuppressive regimen and a regimen with four months of steroids in the first 
year after renal transplantation. This thesis, chapter 7. 
 19.  Vincenti F, Lantz M, Birnbaum J et al. A phase I trial of humanized anti-interleukin 2 receptor 
antibody in renal transplantation. Transplantation 1997;63:33-38. 
 20.  Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft 
pathology. Kidney Int 1999;55:713-23. 
 21.  Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41. 
 22.  Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial 
infections, 1988. Am J Infect Control 1988;16:128-40. 
 23.   Report of the expert committee on the diagnosis and classification of diabetes mellitus. 
Diabetes Care 2003;26 Suppl 1:S5-20. 
 24.  Alarcon-Zurita A, Munar MA, Losada P et al. Steroids withdrawal after 3 months of successful 
renal transplantation using a tacrolimus- and mycophenolate-based immunosuppression. 
Transplant Proc 2002;34:118-19. 
 25.  Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination 
with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate 
mofetil after cadaveric kidney transplantation. Transplantation 2000;69:834-41. 
 26.  Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled 
trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. 
Lancet 1996;348:643-48. 
 27.  Hilbrands LB, Hoitsma AJ, Koene RA. Randomized, prospective trial of cyclosporine 
monotherapy versus azathioprine-prednisone from three months after renal transplantation. 
Transplantation 1996;61:1038-46. 
 28.  van Acker BA, Prummel MF, Weber JA, Wiersinga WM, Arisz L. Effect of prednisone on renal 
function in man. Nephron 1993;65:254-59. 
chapter 6   
 82
 29.  Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous 
kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized 
study. Transplantation 2003;75:1260-66. 
 30.  ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are 
sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001;72:1709-10. 
 31.  Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-
2R antibody induction protocol after primary kidney transplantation. Am J Transplant 
2002;2:568-73. 
 32.  Eckhoff DE, McGuire B, Sellers M et al. The safety and efficacy of a two-dose daclizumab 
(zenapax) induction therapy in liver transplant recipients. Transplantation 2000;69:1867-72. 
 33.  Baan CC, Knoop CJ, van Gelder T et al. Anti-CD25 therapy reveals the redundancy of the 
intragraft cytokine network after clinical heart transplantation. Transplantation 1999;67:870-76. 
 34.  Baran DA, Ashkar J, Galin ID et al. Tacrolimus and new onset diabetes mellitus: the effect of 
steroid weaning. Transplant Proc 2002;34:1711-12. 
 35.  Shapiro R, Jordan ML, Scantlebury VP et al. A prospective randomized trial of FK506-based 
immunosuppression after renal transplantation. Transplantation 1995;59:485-90. 
 36.  Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the 
lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. 
Transplantation 1992;54:868-71. 
 37.  Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 
2001;72:S5-S8. 
 38.  Riou JP, Cohen JR, Johnson H, Jr. Factors influencing wound dehiscence. Am J Surg 
1992;163:324-30. 
 Chapter 7 
 
 
Prevention of accelerated bone loss with a steroid-free 
immunosuppressive regimen and a regimen with four months of 
steroids in the first year after renal transplantation.  
A prospective randomized multicenter study. 
 
 
 
CG ter Meulen1, I van Riemsdijk2, RJ Hené3, MHL Christiaans4, GF Borm5, FHM Corstens6, 
T van Gelder2, LB Hilbrands1, W Weimar2, AJ Hoitsma1. 
Submitted 
 
 
1 University Medical Centre Nijmegen, Department of Nephrology 
2 Erasmus Medical Centre Rotterdam, Department of Nephrology 
3 University Medical Centre Utrecht, Department of Nephrology 
4 University Hospital Maastricht, Department of Nephrology 
 5 University Medical Centre Nijmegen, Department of Epidemiology and Biostatistics 
6 University Medical Centre Nijmegen, Department of Nuclear Medicine 
chapter 7   
 84
Abstract 
Steroid-related bone loss is a recognized complication after renal transplantation. In a 
prospective, randomized, multicenter study we compared the influence of a steroid-free 
immunosuppressive regimen to a regimen with limited steroid exposure on the changes in 
bone mass after renal transplantation. A total of 364 patients were randomized to receive 
either daclizumab (1 mg/kg on days 0 and 10 after transplantation; steroid-free group n=186), 
or prednisone (0.3 mg/kg/day tapered to 0 mg at week 16 after transplantation; controls 
n=178). All patients received tacrolimus, mycophenolate mofetil, and during the first three 
days 100 mg prednisolone intravenously. Changes in bone mineral density (BMD) were 
evaluated in 135 patients in the steroid-free group and in 126 controls. The mean (±SD) BMD 
of the lumbar spine decreased slightly in both groups during the first 3 months after 
transplantation (steroid-free: -1.3±4.0% (P<0.01); control group: -2.3±4.2% (P<0.01)). In the 
following months lumbar BMD recovered in both groups (P<0.01), resulting in a lumbar 
BMD at 12 months after transplantation comparable to the baseline value. No difference 
between the groups was found at three months (steroid-free versus controls: +1.0%; 95% 
confidence interval: -0.0% to +2.0%, NS) and at twelve months after transplantation (steroid-
free versus controls: +0.9%; 95% confidence interval: -0.8% to +2.6%, NS). Similar results 
were obtained for the changes in BMD of the femoral neck in both groups. In conclusion, the 
steroid-free regimen results in a comparable preservation of bone mass as the regimen with 
limited steroid exposure.
  bone loss and steroid-free immunosuppression 
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Introduction 
Renal transplant recipients are at increased risk to develop bone fractures compared with the 
healthy population (1). The fracture risk is especially increased early after transplantation (2). 
Low bone mineral density (BMD) has also been shown a risk factor for fractures in renal 
transplant recipients (3-5). During the first six months after transplantation BMD has been 
shown to decrease between 2 and 7% percent in cyclosporine and prednisone treated patients 
(6-11). Hereafter the decrease in BMD seemed to approach the normal age-related level 
(6;12;13). Therefore, prevention of bone loss has its greatest impact in the first period after 
transplantation. Histomorphometric analysis of bone biopsies (8) and several cross-sectional 
studies (12;14;15) indicate a causal relationship between bone loss and the use of 
glucocorticoids in renal transplant recipients. Avoidance of steroids would therefore be an 
attractive option, and several studies suggest that bone loss after transplantation is prevented 
with a steroid-free immunosuppressive regimen (16;17). These studies however were 
performed in a highly selected population (16) or without controls (17). Therefore we 
performed a prospective, randomized, multicenter study to investigate whether a steroid-free 
immunosuppressive regimen prevents accelerated bone loss compared with a regimen with 
limited steroid exposure. In the control group prednisone was tapered to zero in four months 
as the best available alternative to limit accelerated bone loss after transplantation. In another 
article we have described that both regimens resulted in a comparable incidence of biopsy-
proven acute rejection of 12 to 15% (18). The steroid-free regimen was associated with a 
temporary beneficial effect on the cardiovascular risk profile of the renal transplant recipients, 
but also with increased costs.
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Materials and Methods  
Study design 
We performed a randomized trial at four kidney transplantation centers in the Netherlands. 
Patients were assigned either to treatment with daclizumab (steroid-free group) or to 
maintenance treatment with prednisone during the first four months after transplantation 
(controls). Adult recipients of a first or second transplantation from a living related or 
cadaveric donor were eligible for this study. In another paper we have described the exclusion 
criteria, the details of randomization, and the immunosuppressive protocol (18). 
All patients received tacrolimus and mycophenolate mofetil (MMF) as maintenance therapy, 
and prednisolone 100 mg/day intravenously during the first three days after transplantation. 
The steroid-free group received the monoclonal antibody daclizumab (1 mg/kg body weight) 
intravenously one hour before transplantation and once again on day 10-14 after 
transplantation. The control group received prednisone 0.3 mg/kg/day orally for the first two 
weeks and thereafter the prednisone dose was gradually tapered to zero in 16 weeks. Acute 
rejection was primarily treated with methylprednisolone 500-1000 mg intravenously for three 
consecutive days. In case of interruption of tacrolimus or a reduction of the MMF dose below 
1000 mg/day, or treatment with antilymphocyte therapy, administration of prednisone (dose 
0.10-0.15 mg/kg/day) was allowed. Treatment with elementary calcium (500 mg/day) was 
given according to center praxis. 
 
End points 
The end points were the percent change in BMD of the lumbar spine and the femoral neck at 
three and twelve months after transplantation.  
 
Bone densitometry 
Bone mineral density was assessed at two weeks after transplantation (baseline value) with 
subsequent measurements being performed at 3 and 12 months. Bone mineral density (BMD) 
of the lumbar spine (L2-L4 anteroposterior direction) and the femoral neck were measured 
with dual energy X-ray absorptiometry (DXA), using the Hologic QDR 4500 densitometer 
(Hologic Inc., Waltham, MA, USA) in two centers and the Lunar DPX densitometer (Lunar 
Radiation Corp., Los Angeles, CA, USA) in the other two centers. All bone mineral density 
measurements in one patient were performed using the same densitometer. Z scores were 
calculated using the reference database of the densitometer utilized. The coefficient of 
variation (CV) of daily measurements of the lumbar spine phantom was 0.4% to 1.0% in the 
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four centers. The Hologic spine phantom was scanned on each instrument ten times to 
establish instrument cross-calibration values (19). BMD values were transformed to 
standardized values and expressed in mg/cm2 (20). Changes in BMD over the study period 
were expressed as percent change from the baseline value. The technicians who performed 
BMD measurements were not aware of the group assignment of the patients. 
 
Radiography 
A radiograph of the lumbar spine was obtained at baseline. If a vertebral fracture was 
diagnosed, the densitometry result of this vertebra was excluded from the analysis.  
 
Biochemical measurements 
Calcium, phosphorus, and alkaline phosphatase were measured at one month (baseline value), 
3, and 12 months after transplantation by standard autoanalyzer methods. Intact parathyroid 
hormone (iPTH) was assessed before transplantation, and at 3 and 12 months after 
transplantation, using a commercial assay.  
 
Calculations and statistical analyses 
The serum total calcium concentration was adjusted for albumin following the equation: 
Adjusted calcium (mmol/L) = calcium – (0.025 * albumin) + 1 mmol/L (21). The creatinine 
clearance was estimated using the Cockcroft-Gault equation (22).  
Results are given as means ± SD unless stated otherwise. The statistical analyses were 
performed on an intention-to-treat basis, including only patients in whom the changes from 
baseline in BMD could be assessed. In the primary analysis P-values and 95% confidence 
intervals were calculated using t-tests for the difference of continuous variables between the 
groups. Differences with baseline were assessed with paired t-tests. Log transformation was 
performed prior to the analysis where appropriate. Chi-square analysis was performed to 
compare proportions between the two groups. For all tests a P-value less than 0.05 (two-
sided) was considered significant.
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Results  
Patients 
Between October 1999 and March 2002, 381 patients were enrolled. Seventeen patients 
randomized did not receive the allocated regimen for several reasons, leaving 364 patients for 
intention-to-treat analysis (Figure 1). In the steroid-free group and control group 51 and 52 
patients respectively failed to complete a baseline and at least one follow-up DXA 
measurement at the scheduled time. These patients were also excluded from analysis, leaving 
135 patients in the steroid-free group and 126 patients in the control group (Figure 1). The 
BMD measurements were performed at similar time points in the steroid-free and control 
group (baseline: 14±5 versus 13±5 days after transplantation; t= 3 months: 97±11 versus 
98±13 days after transplantation; t= 12 months: 369±22 versus 371±20 days after 
transplantation). The proportion of male patients was higher in the steroid-free group 
compared with the control group. The two groups were not different with respect to the other 
baseline characteristics, as shown in table 1. The baseline characteristics of the patients who 
were excluded from analysis were not different from those included in the analysis. 
 
Immunosuppression and acute rejection episodes 
In accordance with the study design, the control group received more prednisone, especially 
in the first three months after transplantation (Table 2). The number of patients treated with 
methylprednisolone pulse therapy because of a (presumed) rejection was comparable in both 
groups (Table 2). In 36 patients (27%) in the steroid-free group prednisone was started for 
several clinical reasons (intolerance for MMF (n= 13), intolerance for tacrolimus (n=16), the 
occurrence of a (severe) acute rejection (n=5), and other causes (n=2)). At twelve months 
after transplantation 21 patients (16%) in the steroid-free group and 16 patients (13%) in the 
control group were still using prednisone (NS). There was no difference between the groups 
in the proportion of patients treated with bisphosphonates, vitamin D, or patients with a 
parathyroidectomy in the first year after transplantation (Table 2). Bisphosphonates were 
administered because of (symptomatic) hypercalcemia (n=16), and for unknown reason (n=2). 
Vitamin D was administered because of a history of parathyroidectomy (n=4), treatment of 
hyperparathyroidism (n=2), vitamin D deficiency (n=1) and for unknown reasons (n=3). 
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Table 1. Baseline characteristics of patients.  
Characteristic 
Steroid-free  
N= 135 
Control 
N= 126 
Median (range) age patients (years) 50 (21-78) 49 (19-73) 
Number of male patients (%) 103 (76) a 72 (57) 
Number of pre-/ postmenopausal women 17/15 26/28 
Body weight (kg) 75±14 73±15 
Body mass index (kg/m2) 25±4 25±5 
Number of patients (%) with diabetes mellitus 15 (11) 9 (7) 
Number of patients (%) with bone fractures b 6 (4) 6 (5) 
Number of patients (%) with total parathyroidectomy 2 (2) 2 (2) 
Hemodialysis/ peritoneal dialysis/ no dialysis 67/ 50/ 18 62/ 51/ 13 
Median (range) duration of dialysis (months) c 32 (1-245) 30 (2-111) 
First/second graft (n) 123/ 12 113/ 13 
Bone mineral density of lumbar spine (mg/cm2) 1118±188 1091±178 
Z score  d -0.4±1.5 -0.4±1.4 
Bone mineral density of femoral neck (mg/cm2) 821±153 816±147 
Z score  d -0.6±1.2 -0.6±1.2 
a P<0.05 between groups. 
b History of fracture or fracture at X-ray of the lumbar spine at baseline. 
c Excluding patients transplanted before renal replacement therapy was started. 
d SD of age-matched and gender-matched controls.
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Bone mineral density measurements and fractures 
At baseline, BMD was similar in the two groups at both skeletal sites (Table 1). At three 
months as well as at twelve months after transplantation, the percent change in BMD at any 
site was not different between both groups (Figure 2). In the first three months after 
transplantation, lumbar BMD decreased significantly (P<0.01) in the steroid-free (-1.3±4.0%) 
and in the control group (-2.3±4.2%) (difference between groups: +1.0% (95% CI: -0.0 to 
+2.0; NS)). During the following months there was a significant recovery of lumbar BMD in 
Figure 1. Flow diagram of the patients randomized to one of the treatment groups. 
Randomized (n=381) 
Eligible for intention-to-treat analysis (n=186)
Allocated to steroid-free group (n=192) 
Did not receive allocated regimen: 
      •Not transplanted (n=3) 
      •Not meeting inclusion criteria (n=2) 
      •Unknown reason (n=1) 
 
Allocated to control group (n=189) 
Did not receive allocated regimen: 
      •Not transplanted (n=3) 
      •Not meeting inclusion criteria (n=4) 
      •Unknown reason (n=4) 
Eligible for intention-to-treat analysis (n=178) 
Not enough DXA measurements: 
      •Patient death (n=7) 
      •Graft failure (n=13) 
      •Unknown reason (n=31) 
Not enough DXA measurements: 
      •Patient death (n=10) 
      •Graft failure (n=15) 
      •Unknown reason (n=27) 
Analyzed (n=135) Analyzed (n=126) 
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both groups (P<0.01), resulting in a lumbar BMD at 12 months after transplantation 
comparable with baseline in both groups (difference between groups: +0.9% (95% CI: -0.8 to 
+2.6; NS)).  
BMD of the femoral neck also decreased significantly (P<0.05) in both groups (-1.4±5.1%) 
during the first three months after transplantation (difference between groups: -0.0% (95% CI: 
-1.3 to +1.3; NS)). In the following months there was a non-significant recovery of femoral 
neck BMD in both groups, resulting in a BMD of the femoral neck at 12 months after 
transplantation which was comparable to the baseline value in the steroid-free group and 
control group (difference between groups: -0.1% (95% CI: -2.2 to +1.9; NS)). Adjustment for 
the imbalance in gender between the treatment groups by covariate analysis did not essentially 
change the results.  
In the steroid-free group 70 patients (52%), were not treated with prednisone or 
methylprednisolone pulse therapy during follow-up. The changes in BMD of the lumbar spine 
and femoral neck in this subgroup were also not different from the changes in the control 
group. However, the percent of lumbar BMD lost at twelve months after transplantation in 
patients who were still using prednisone at twelve months after transplantation (-2.2±8.3%) 
was significantly (p<0.05) larger compared with the patients who did not use prednisone 
(+0.7±6.3%) (difference between groups: -2.9%; 95% CI: -0.4 to -5.4). During follow-up 
fractures of the ribs occurred in three patients (steroid-free versus control group: 2 versus 1). 
 
Renal function 
The creatinine clearance was comparable in the steroid-free and the control group at three and 
twelve months after transplantation (t=3 months: 55±19 versus 57±18 ml/min; t=12 months: 
67±21 versus 62±20 ml/min). In the population analyzed, graft failure occurred in three 
patients in each group during follow-up. 
 
Biochemical measurements 
Biochemical data are summarized in Table 3. The serum concentrations of adjusted calcium, 
and phosphorus were significantly higher in the steroid-free group compared with the control 
group at one month after transplantation. Hereafter these differences disappeared (Table 3). 
The serum concentration of parathyroid hormone decreased in the first three months after 
transplantation in both the steroid-free and control group. Thereafter the serum concentration 
of parathyroid hormone stabilized, albeit at slightly elevated levels in both groups. In both 
groups alkaline phosphatase increased slightly compared with baseline. 
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Table 2. Treatment with corticosteroids, bisphosphonates, vitamin D, and parathyroidectomy during 
the first 12 months after transplantation. 
 
Steroid-free 
N=135 
Control 
N=126 
Median (range) cumulative prednisone dose (mg) a   
0-3 months 300 (275-3648) b 1430 (942-2265)
3-12 months 0 (0-4585) b 98 (0-3572) 
Number (%) of patients treated with methylprednisolone 
pulse therapy c 
  
0-3 months 37 (27) 24 (19) 
3-12 months 5 (4) 5 (4) 
Number (%) of patients treated with calcium carbonate 80 (59) 70 (56) 
Number (%) of patients treated with bisphosphonates 11 (8) 7 (6) 
Number (%) of patients treated with vitamin D 7 (5) 3 (2) 
Number of patients treated with parathyroidectomy after 
transplantation 
3 (2) 4 (3) 
a Excluding methylprednisolone pulse therapy given in case of a (presumed) acute rejection. 
b P <0.001. 
c As given in case of a (presumed) acute rejection. 
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Figure 2. Mean (±SE) change in the bone mineral density of the lumbar spine (top panel), and 
femoral neck (bottom panel) in the steroid-free and control groups. (*: P< 0.05 versus baseline; # 
P<0.05 versus month 3). 
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Discussion 
To our knowledge, this is the first large prospective randomized study that compared the 
influence of a steroid-free immunosuppressive regimen to a regimen with four months 
corticosteroid therapy on the change in bone mass during the first year after renal 
transplantation. The data show that the average change in bone mass during twelve months 
after transplantation was comparable with both regimens. Apparently the usage of a moderate 
dose of steroids during four months after transplantation had no important influence on the 
change in bone mass during the first year after transplantation. The study was population 
based and did not select patients on the presence of osteoporosis or particular causes of renal 
osteodystrophy. The scheduled BMD measurements could be performed in the majority of the 
patients eligible for intention-to-treat analysis. Patients that were not included in the analysis 
because of lacking BMD measurements were not different with respect to baseline 
characteristics.  
By design of the study, differences between the groups in the change in bone mass should be 
expected at three months after transplantation. However, despite a clear difference between 
the groups in the cumulative steroid dose, bone mass decreased at a comparable low rate in 
both groups at three months after transplantation. A tendency to decreased bone loss of the 
lumbar spine was found in the steroid-free group. Therefore, a small beneficial effect of the 
steroid-free immunosuppressive regimen on bone mass is not excluded by our study. Larger 
study populations are needed to detect such a small difference. Furthermore, we cannot 
exclude that the change in bone mass has temporarily diverged between the groups later on, 
due to additional bone loss in the control group during the first period after cessation of 
steroids. However, no such decrease was seen in a small study at three months after 
withdrawal of corticosteroids (23). Moreover, the 70 patients in the steroid-free group that did 
not receive any prednisone maintenance therapy or methylprednisolone pulses had a 
comparable small but transient decrease in lumbar BMD. We therefore conclude that 
maintenance therapy with prednisone does not explain the initial transient decrease in BMD, 
and other factors must be implicated. Besides (partial) resolution of preexistent renal 
osteodystrophy, immobilization after the operation might be involved (24). The effect on bone 
mineral density of three days of 100 mg prednisolone intravenously, as administered to the 
whole study population, is unclear. However, in a cohort of 17 patients with multiple 
sclerosis, no decrease in BMD was found at two and four months after treatment of 1000 mg 
methylprednisolone intravenously during three days (25). 
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In the period between three and twelve months after transplantation bone mineral density 
recovered, and the average bone mass was comparable to the baseline value in both groups at 
one year after transplantation. At that time, the immunosuppressive treatment was similar in 
both groups, and more than 80% of the patients were off steroids. Preservation of bone mass 
was also reported in previous small or uncontrolled trials in patients treated with a steroid-free 
regimen (16). In our opinion a steroid-free regimen or a regimen with limited steroid exposure 
seems the best available option for prevention of accelerated bone loss after transplantation. 
Considering the tendency to preserved lumbar BMD in the group treated with the steroid-free 
regimen, this regimen might be preferred in patients at high risk for bone fractures. If 
treatment with corticosteroids is necessary for more than four months after transplantation, 
prophylactic treatment should be considered. Treatment with vitamin D and calcium (7) as 
well as treatment with bisphosphonates (26;27) have been shown to (partially) prevent 
accelerated bone loss in renal transplant recipients who continued prednisone in combination 
with cyclosporine and MMF.  
 
Our study has limitations, and the results should be interpreted in the context of its design. 
BMD is a surrogate marker, and we do not know the effect of the preservation of BMD on the 
actual bone fracture rate in this population. In our study only three patients experienced a 
fracture (of the ribs in all cases) during the follow-up period of 12 months, so no conclusions 
can be drawn on this outcome parameter. However, several studies have shown a similar 
relationship between low BMD and the risk of fractures in renal transplant recipients as in the 
normal population (3;4).  
 
In summary, our study indicates that a steroid-free tacrolimus based regimen with induction 
therapy with daclizumab does not result in a stronger preservation of bone mass than a 
regimen with four months of steroid therapy. On average, both regimens prevented 
accelerated bone loss in the first year after renal transplantation. 
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Abstract  
Steroid-related bone loss is a recognized complication after renal transplantation. Quantitative 
ultrasound (QUS) of bone measures bone structure besides bone mass. We investigated the 
influence of corticosteroid therapy on QUS parameters during the first year after renal 
transplantation. A total of 119 renal transplant recipients were randomized to receive either a 
steroid-free regimen or a regimen with prednisone during four months. In 96 patients (steroid-
free: n=49, controls: n=47), QUS parameters of the right calcaneus, and dual energy X-ray 
absorptiometry (DXA) parameters of the lumbar spine and the right hip were measured at 
baseline, three, and twelve months after transplantation. Despite a significant difference in 
steroid use between the two groups, there was no difference between the two groups in QUS 
and DXA parameters at any time point. BMD of the lumbar spine decreased at three months 
and recovered hereafter to the baseline value. BMD of the femoral trochanter decreased at 
three months and remained stable hereafter. In contrast, the QUS parameter broadband 
ultrasound attenuation (BUA) continued to decrease between three and twelve months after 
transplantation (steroid-free versus steroids: -4.1% (P<0.05) versus -2.6% (P<0.05) at twelve 
months compared with baseline). It is concluded, that the usage of a moderate dose of steroids 
during four months after renal transplantation did not influence QUS parameters of the 
calcaneus. While bone mass remained stable or improved between three and twelve months 
after transplantation, the decrease in BUA seems to reflect a continuing change in bone 
structure in this population with preexistent renal osteodystrophy. 
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Introduction 
Recipients of a renal transplant are at increased risk to develop bone fractures (1). Renal 
osteodystrophy and corticosteroid-induced bone loss are important factors involved. Bone 
mineral density as measured with dual energy X-ray absorptiometry (DXA) has been shown 
to decrease by 2-7 percent in cyclosporine and prednisone treated patients in the first year 
after renal transplantation (2-7). However, a low bone mineral density only partly explains the 
increased fracture rate in renal transplant recipients (8;9). Other factors which are not assessed 
by DXA, as the microarchitecture and the elasticity of bone are also related with the strength 
of the bones. Renal osteodystrophy is characterized by a disturbed microarchitecture of bone 
and is a common finding in histomorphometric studies of patients with renal insufficiency 
(10;11). Quantitative ultrasound (QUS) measurement of bone is a relatively new non-invasive 
technique that appears to assess microarchitecture and elasticity in addition to bone mineral 
density (12). Compared with DXA, QUS is cheaper, is relatively easy to use, takes up less 
space, and it does not employ ionizing radiation. Most of the commercially available 
ultrasound devices have been developed for measurement of the calcaneus, as this bone 
contains a high percentage of trabecular bone mimicking that of the spine and the hip (13). 
The QUS parameters broadband ultrasound attenuation (BUA) and velocity or speed of sound 
(SOS) are the two most commonly used. In older healthy women, a low BUA of the calcaneus 
has been shown to predict hip fractures, independent of DXA (14;15). To our knowledge 
there are no controlled studies investigating the influence of corticosteroids on QUS 
parameters in recipients of a renal transplant. It is unclear whether QUS is able to measure 
other properties of bone compared with DXA in recipients of a renal transplant. 
In a prospective randomized study, we compared the influence of a steroid-free 
immunosuppressive regimen with a regimen with four months corticosteroid therapy on QUS 
and DXA parameters during the first year after renal transplantation. 
chapter 8   
 102
Materials and method 
Study population and study design 
Patients participated in a prospective randomized controlled multicenter trial (16). All 119 
patients included at the University Medical Center Nijmegen, the Netherlands were studied. 
Patients were assigned either to treatment with daclizumab (steroid-free group) or to 
maintenance treatment with prednisone during the first four months after transplantation 
(controls). Adult recipients of a first or second transplantation from a living related or 
cadaveric donor were eligible for this study. In another paper, we have described the 
exclusion criteria, the details of randomization, and the immunosuppressive protocol (16). 
In summary, all patients received tacrolimus and mycophenolate mofetil (MMF) as 
maintenance therapy, and prednisolone 100 mg/day intravenously during the first three days 
after transplantation. The steroid-free group received the humanized monoclonal antibody 
daclizumab (1 mg/kg body weight) intravenously one hour before transplantation and once 
again on day 10-14 after transplantation. The control group received prednisone 0.3 
mg/kg/day orally for the first two weeks and thereafter the prednisone dose was gradually 
tapered to zero in 16 weeks. Acute rejection episodes were primarily treated with 
methylprednisolone 500-1000 mg intravenously for three consecutive days. In case of 
interruption of tacrolimus, or a reduction of the MMF dose below 1000 mg/day, or treatment 
with antilymphocyte therapy, administration of prednisone (dose 0.10-0.15 mg/kg/day) was 
allowed. Treatment with elementary calcium (500 mg/day) was given, except to patients 
having hypercalcemia. 
 
Analytical methods 
Both QUS and DXA measurements were performed at baseline, at 3, and at 12 months after 
renal transplantation, preferably at the same visit. QUS measurements of the right heel were 
performed using the ultrasound bone imaging scanner UBIS 3000 (DMS, Montpellier, 
France) by scanning the calcaneus in two directions using a pair of 0.5 MHz focussed 
broadband transducers with a diameter of 25 mm, immersed in a water bath at 30 °C. The 
acoustic properties broadband ultrasound attenuation (BUA, dB/MHz) and speed of sound 
(SOS, m/s) were assessed. These ultrasound parameters were measured in a circular region 
(14 mm) with the lowest attenuation in the posterior part of the calcaneus using a computer 
algorithm for automatic detection of this region (17). The same operator performed all 
measurements in order to minimize operator and technical intervariability. The heel of each 
patient was measured twice with complete repositioning between measurements. If the first 
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two measurements differed by 10 dB/MHz or more, a third measurement was obtained. 
Therefore, the definitive result was the mean of two or three measurements. The short-term 
precision error was calculated at 3.4% for BUA and at 0.38% for SOS (18). Internal acoustic 
phantoms were scanned before every measurement and the results showed no drift over the 
period of the study.   
BMD was measured by dual energy X-ray absorptiometry (DXA) using a Hologic QDR-4500 
(standard array mode). Each subject was measured at the anteroposterior lumbar spine (L1-
L4), total hip, femoral neck and trochanter. Standard procedures supplied by the manufacturer 
for scanning and analyses were followed. Calibration procedures were performed every day 
and after series of eight scans using the appropriate phantoms provided by the manufacturer. 
The coefficient of variation for DXA measurements (lumbar phantom scans) was 0.4%. BMD 
at the lumbar spine, femoral neck, trochanter, and total hip DXA was expressed in g/cm2 and 
in Z-scores according to the database delivered by Hologic. 
 
Data and statistical analysis 
Results are given as means ± SD unless stated otherwise. QUS and BMD changes in the study 
period were expressed as a percentage of the baseline value. The statistical analyses were 
performed on an intention-to-treat basis, including only patients in whom the changes from 
baseline in QUS parameters could be assessed. Comparison of continuous variables between 
the groups was performed using unpaired t tests. Changes from baseline were assessed with 
paired t-tests. Log transformation to normalize the distribution of the data, was performed 
prior to the analysis where appropriate. Chi-square analysis was performed to compare 
proportions between the two groups. Linear associations between the different parameters 
were determined by calculation of the Pearson correlation coefficients. For all tests a P-value 
less than 0.05 (two-sided) was considered significant. 
 
 
 
Results 
Between November 1999 and March 2002, 119 patients were enrolled (Figure 1). Six patients 
did not receive the allocated regimen for several reasons, leaving 113 patients for intention-to-
treat analysis. Additionally, 17 patients were excluded because of failure to complete a 
baseline and at least one follow-up QUS measurement at the scheduled time. These patients 
were also excluded from the analysis, leaving 49 patients in the steroid-free group and 47 
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patients in the control group. The QUS measurements were performed at similar time points 
in the steroid-free and control group (baseline: 14±4 versus 15±4 days after transplantation; 
t=3 months: 98±10 versus 99±13 days after transplantation; t=12 months: 370±13 versus 
366±15 days after transplantation). The proportion of male patients was higher in the steroid-
free group (Table 1). The two groups were not different with respect to the other baseline 
characteristics as shown in table 1. 
 
 
 
Table 1. Baseline characteristics of patients. 
Characteristic 
Steroid-free 
(N=49) 
Control 
(N=47) 
Age (years) 49±14 47±14 
Number of male patients (%) 39 (80) a 24 (51) 
Number of pre-/ postmenopausal women 3/ 7 10/ 13 
Body weight (kg) 75±11 72±13 
Body mass index (kg/m2) 24±3 25±4 
Hemodialysis/ peritoneal dialysis/ no dialysis  19/ 22/ 8 27/ 15/ 5 
Median (range) duration of dialysis (months) b 36 (4-98) 34 (2-83) 
Number of patients (%) with previous bone fractures 2 (4) 2 (4) 
Median (range) serum parathyroid hormone (pmol/L) c 18 (2-158) 14 (2-160) 
Bone mineral density of lumbar spine (g/cm2) 0.973±0.153 0.984±0.157 
             Z-score -0.5±1.3 -0.2±1.6 
Bone mineral density of total femur (g/cm2) 0.912±0.147 0.900±0.164 
             Z-score -0.5±1.0 -0.4±1.4 
Bone mineral density of femoral neck (g/cm2) 0.806±0.134 0.812±0.136 
             Z-score -0.3±1.1 -0.2±1.4 
Bone mineral density of femoral trochanter (g/cm2) 0.714±0.130 0.698±0.129 
             Z-score -0.2±1.1 -0.1±1.3 
BUA (dB/mHz) 71±16 72±18 
SOS (m/s) 1509±36 1504±33 
a P<0.05 versus control group. 
b Excluding patients transplanted before renal replacement therapy was started. 
c The normal reference range for serum parathyroid hormone is 1 to 6.5 pmol/L.
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Immunosuppression and acute rejection episodes 
In accordance with the study design, the control group received more prednisone, with the 
largest difference in the first three months after transplantation (Table 2). The number of 
patients treated with methylprednisolone pulse therapy because of a (presumed) rejection was 
comparable in both groups (Table 2). In 21 patients (43%) in the steroid-free group, 
prednisone was started for several clinical reasons (intolerance for MMF (n= 11), intolerance 
for tacrolimus (n=6), the occurrence of a (severe) acute rejection (n=3), and other causes 
Figure 1. Flow diagram of the patients randomized to one of the treatment groups. 
Randomized (n=119) 
Eligible for intention-to-treat analysis (n=57) 
Allocated to steroid-free group (n=59) 
Did not receive allocated regimen: 
      •Not transplanted (n=2) 
      •Not meeting inclusion criteria (n=0) 
 
 
Allocated to control group (n=60) 
Did not receive allocated regimen: 
      •Not transplanted (n=1) 
      •Not meeting inclusion criteria (n=3) 
Eligible for intention-to-treat analysis (n=56) 
Not enough QUS measurements: 
      •Deformities of the feet (n=1) 
      •Graft failure (n=2) 
      •Protocol failure (n=5) 
Not enough QUS measurements: 
      •Patient death (n=2) 
      •Protocol failure (n=6) 
      •Deformities of the feet (n=1) 
Analyzed (n=49) Analyzed (n=47) 
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(n=1)). At twelve months after transplantation, eight patients in both groups were still using 
prednisone. There was no difference between the groups in the proportion of patients treated 
with bisphosphonates, or a parathyroidectomy in the first year after transplantation (Table 2). 
 
 
 
 
Table 2. Treatment with corticosteroids, bisphosphonates, and parathyroidectomy during the first 12 
months after transplantation. 
 Steroid-free 
(N=49) 
Control 
(N=47) 
Median (range) cumulative prednisone dose (mg) a   
0-3 months 300 (300-2385) b 1412 (942-2280)
3-12 months 0 (0-5165) b 95 (26-3012) 
Number (%) of patients treated with methylprednisolone pulse therapy c   
0-3 months 15 (31) 12 (26) 
3-12 months 1 (2) 1 (2) 
Number (%) of patients treated with bisphosphonates d  10 (20) 4 (9) 
Number of patients treated with parathyroidectomy after transplantation 3 (6) 3 (6) 
a Excluding methylprednisolone pulse therapy given in case of a (presumed) acute rejection. 
b P<0.001 
c As given in case of a (presumed) acute rejection. 
d As given in case of hypercalcemia 
 
 
 
BMD and QUS changes 
The mean (±SE) changes in BMD and QUS parameters during the first year after 
transplantation are shown in figure 2, 3 and 4. There were no differences between the groups 
in the changes in BMD or QUS parameters at any time point (Table 3).  
However, compared with baseline, significant changes in BMD and QUS parameters were 
detected in both groups. In the control group, BMD of the lumbar spine and the total hip 
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decreased in the first three months after transplantation (-2.2±3.1%; P<0.001 and -1.2±3.3%; 
P<0.05, respectively), and returned to the baseline value at twelve months after 
transplantation (Figure 2). In the steroid-free group, no significant changes were found for 
these parameters at three months (lumbar spine: -1.1±4.3%; P=0.09 and total hip: -0.5±4.1%; 
NS) and at twelve months after transplantation (Figure 2). The BMD of the femoral trochanter 
decreased in the steroid-free and control group at three months after transplantation (-
1.4±5.3%; P<0.05 and -2.0±3.9%; P<0.01) and remained below the baseline level in both 
groups at twelve months after transplantation (-2.2±8.6%; P<0.05 versus -1.8±7.8%; P<0.05) 
(Figure 3). 
The QUS parameter BUA was significantly lower at twelve months after transplantation 
compared with baseline in the steroid-free and control group (-4.1±10.3% (P<0.01) and -
2.6±10.0% (P<0.05), respectively (Figure 4). In contrast to the DXA parameters, BUA 
continued to decrease (P<0.05) between three and twelve months after transplantation in both 
groups. SOS decreased significantly in the steroid-free group at three months after 
transplantation (-0.3±0.8%; P<0.01), and returned to the baseline value at twelve months after 
transplantation. No significant changes in SOS were found in the control group. 
Exclusion of the patients in the steroid-free group who were treated with steroids during 
follow-up did not change the results. In addition, correction for gender with covariance 
analysis did not change the results. 
 
Table 3. Percentage difference (95% confidence interval of difference) between the groups in 
the change in BMD and QUS parameters at three and twelve months after transplantation. 
 Percentage difference between the steroid-free and control group 
(95% confidence interval of difference)  
 Three months  Twelve months 
Lumbar spine BMD +1.1 (-0.5 to +2.7) +0.4 (-2.0 to +2.8) 
Total hip BMD +0.8 (-0.8 to +2.4) -0.0 (-3.0 to +2.9) 
Femoral neck BMD -0.4 (-2.6 to +1.9) -0.4 (-4.2 to +3.4) 
Femoral trochanter BMD +0.6 (-1.4 to +2.6) -0.4 (-3.9 to +3.1) 
BUA -0.7 (-2.9 to +1.6) -1.5 (-5.7 to +2.7) 
SOS -0.14 (-0.49 to +0.21) -0.25 (-0.79 to +0.28) 
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Correlation between (changes in) QUS and DXA parameters 
At baseline the correlation between BUA and BMD was moderate ranging from r=0.55 for 
the femoral neck to r=0.66 for the femoral trochanter (P<0.001). There was no significant 
correlation between the percent changes in the BUA and the percent changes in BMD 
between zero and three months after transplantation. Regarding the entire study period from 
zero to twelve months after transplantation, the percent changes in BUA were significantly 
correlated with the percent changes in BMD (r= 0.32, r= 0.54, r= 0.52, r=0.58, all P<0.01, for 
the lumbar spine, total hip, femoral neck, and trochanter BMD, respectively). Between three 
and twelve months after transplantation, the percent changes in BUA were also significantly 
correlated with the percent changes in BMD (r= 0.30, r= 0.50, r= 0.40, r=0.51, all P<0.01, for 
the lumbar spine, total hip, femoral neck, and trochanter BMD, respectively). 
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Figure 2. Mean percent change (±SE) from baseline in the bone mineral density of the lumbar 
spine (top panel), and total hip (bottom panel) in the steroid-free and control groups. 
(*: P< 0.05 versus baseline; #: P<0.05 versus month 3). 
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Figure 3. Mean percent change (±SE) from baseline in the bone mineral density of the femoral neck 
(top panel), and femoral trochanter (bottom panel) in the steroid-free and control groups. 
(*: P< 0.05 versus baseline). 
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Figure 4. Mean percent change (±SE) from baseline in QUS parameters in the steroid-free and 
control groups. BUA, broadband ultrasound attenuation (top panel); SOS, speed of sound (bottom 
panel). (*: P< 0.05 versus baseline; #: P<0.05 versus month 3). 
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Discussion 
This is the first prospective randomized study comparing the influence of a steroid-free 
immunosuppressive regimen to a regimen with limited steroid exposure on quantitative 
ultrasound parameters of the calcaneus after renal transplantation. The data show, that the 
average change in QUS parameters was comparable with both regimens. Apparently, no 
additional influence of a moderate dose of steroids was found on QUS parameters during 
twelve months after transplantation. So far, cross-sectional studies have reported a decrease 
(19-23) in QUS parameters in other populations using glucocorticoids. As QUS parameters 
are highly influenced by bone mass (24), the decreased QUS parameters reported in these 
studies parallel the well-known decrease in bone mass of patients treated with glucocorticoids. 
In this longitudinal study however, the course of BMD as assessed by DXA and QUS was not 
influenced by a moderate dose of steroids. Moreover, the microarchitecture and elasticity of 
bone as measured by QUS, were not influenced by about ±1200 mg of prednisone given 
during the first year after transplantation. 
 
Of interest, the time course of the changes in the QUS parameter BUA seemed different from 
the changes in DXA parameters. While DXA parameters remained more or less stable or 
decreased temporary, the average BUA continued to decrease in both groups between three 
and twelve months after transplantation. We consider the decrease of BUA during the first 
year after transplantation as a ‘real change’, since the measured difference exceeded the 
precision error, and the calibration procedures showed no drift of the QUS device during the 
study. Furthermore, the annual decrease of BUA in our study is clearly larger than the 
reported annual rate of change in pre- and postmenopausal women (25). BUA is related to 
bone mineral density as well as to the microarchitecture of trabecular bone (12). The decrease 
in BUA might be the result of a regional decrease in BMD of the calcaneus. We did not 
measure the BMD of the calcaneus, but considering the stable BMD of the femoral neck and 
trochanter, or even the improved BMD of the lumbar spine between three and twelve months 
after transplantation, it is not likely that the continued decrease in BUA can be explained by a 
decrease in calcaneal BMD. Other longitudinal studies demonstrated that changes in BMD of 
the calcaneus followed the changes in BMD of the lumbar spine and the femoral neck (26;27). 
Individually, the changes in BUA were only moderately correlated with the changes in BMD. 
The variation in the change in BUA was explained by the change in BMD of the lumbar spine 
and hip for maximal 34 percent. This underlines that the changes in BUA are only marginally 
explained by changes in bone mineral density in this population. Since BUA is related to 
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density as well as to bone structure (12), it is possible that the average change in BUA found 
in this study reflect a change in bone structure but not density after renal transplantation. A 
cross-sectional study in renal transplant recipients, demonstrated that BUA and SOS 
correlated to trabecular bone histomorphometry (9), however, it is unclear from this study if 
this relation was independent of BMD. Prospective studies with respect to the changes in 
QUS parameters, BMD, and bone structure as assessed by bone histomorphometry may add 
additional information regarding the change of bone properties after transplantation. 
 
The relative change in SOS in our study was very marginal, which is inherent to the 
parameter. The change in SOS during aging from 20 to 80 years is limited to ±5 percent of the 
baseline value (25). The pattern of the changes in the QUS parameter SOS was comparable to 
the changes in BMD of the lumbar spine and total hip, although changes were only detected in 
the steroid-free group.  
 
So far, only one prospective, uncontrolled study addressed the changes in QUS parameters 
after renal transplantation (28). In contrast to our study, no changes in the QUS parameters 
BUA and SOS of the calcaneus were found in 46 cyclosporine, mycophenolate mofetil and 
prednisone treated patients during the first six months after transplantation. In this study, a 
QUS device without imaging techniques was used, while in our study QUS parameters were 
measured with an imaging device in the region of lowest attenuation. Furthermore, the follow-
up of this study was shorter, and the sample size smaller compared with our study. These 
aspects influence the ability to measure a longitudinal change in QUS parameters. It is unclear 
whether BUA in our study population will continue to decrease at longer follow-up. In two 
cross-sectional studies (29;30) there was no relation reported between the time after 
transplantation and QUS parameters, which might indicate that BUA stabilizes at longer 
follow-up. Besides the fact that these are cross-sectional data, both studies were also 
performed with a non-imaging device. 
A low BUA of the calcaneus has been shown to predict hip fractures (14;15;31). Information 
with regard to the fracture incidence is limited in renal transplant recipients. In one cross-
sectional study, a low SOS was associated with increased fracture incidence in female renal 
transplant recipients (9). However, no difference was found in BUA between patients with or 
without a fracture. Our study delivers no additional information, since no fractures occurred 
during the first year after renal transplantation. 
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In conclusion, QUS parameters of the calcaneus are not influenced by a limited dose of 
corticosteroids during the first four months after renal transplantation. In contrast to DXA 
parameters, the average BUA continued to decrease after transplantation in both groups. This 
continued decrease in BUA might be a reflection of a change in bone structure in this 
population with preexistent renal osteodystrophy. At present, the relevance of this finding is 
unclear. 
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In the last two decades, the results of renal transplantation have tremendously improved by the 
availability of new and potent immunosuppressive drugs. However, recipients of a renal 
transplant often experience several side effects specifically related to these immunosuppressive 
drugs, such as an increase in cardiovascular risk factors leading to cardiovascular morbidity, 
increased susceptibility to infections and malignancies, and increased bone loss leading to bone 
fractures. Therefore, finding the balance between adequate immunosuppression and the 
occurrence of side effects is an important clinical problem.  
 
Monoclonal antibodies directed against the alpha chain of the interleukin-2 receptor (IL-2Rα), 
are drugs with a highly specific immunosuppressive mechanism of action. Induction therapy 
with these agents was not associated with an increased incidence of adverse events, and seems 
an important advance in the above-mentioned balance. Therefore these agents may prove 
particularly advantageous in the treatment of transplant recipients. 
In chapter two, we provide an overview of the available monoclonal antibodies against IL-
2Rα and its use in renal transplantation. Basiliximab is a chimeric monoclonal antibody, 
daclizumab a humanized antibody directed against IL-2Rα. In our studies we have used 
daclizumab as induction therapy. Daclizumab has been traditionally administered in a five-
dose regimen after transplantation. The first infusion is administered intravenously one hour 
before transplantation and once again every two weeks. So patients have to come to the 
hospital to receive these infusions. Besides, daclizumab is very expensive. On theoretical 
grounds, we have decided to administer only two doses of daclizumab after transplantation. In 
chapter three we demonstrated that a two-dose regimen of daclizumab in combination with 
tacrolimus and mycophenolate mofetil resulted in a blockade of the IL-2Rα-chain, which 
lasted for more than 10 weeks after transplantation. The two-dose regimen of daclizumab in 
combination with tacrolimus and mycophenolate mofetil seemed sufficient for adequate 
immunosuppression as was suggested by a low incidence of acute rejection (13%).  
 
In the following two chapters, the development of an alternative method for monitoring IL-
2Rα blockade of lymphocytes is described. Soluble IL-2Rα is the truncated form of the alpha 
chain of the IL-2 receptor and is derived from proteolytic cleavage of membrane bound IL-
2Rα. Soluble IL-2Rα is filtered by the kidney and excreted with the urine. We hypothesized 
that excess daclizumab would bind to the IL-2Rα on peripheral lymphocytes, as well as to 
soluble IL-2Rα in serum. In the following experiments we observed a decreased renal 
  summary 
 121
excretion of IL-2Rα during daclizumab treatment (chapter four). It seems likely that binding 
of daclizumab to soluble IL-2Rα leads to the formation of a large complex thus preventing 
glomerular leakage of soluble IL-2Rα. Thus we concluded that measurement of urinary 
soluble IL-2Rα may provide information on the concentration of anti-IL-2Rα mAb in serum. 
We have compared urinary measurements of soluble IL-2Rα with the golden standard, flow 
cytometry (chapter five); from the data we can conclude that IL-2Rα blockade of peripheral 
lymphocytes after treatment with daclizumab can reliably be assessed by calculation of the 
fractional excretion of soluble IL-2Rα. This method is easier to use, compared with the 
current gold standard, flow cytometric analysis of IL-2Rα on lymphocytes. 
 
In chapter six and seven, we describe our studies specifically aimed at the evaluation of the 
use of daclizumab as replacement therapy for steroids after renal transplantation. The use of 
corticosteroids is associated with several well-documented side effects such as hypertension, 
hyperlipidemia, new-onset diabetes mellitus, infections, and accelerated bone loss. In a 
prospective, randomized, multicenter study the avoidance of steroids by the administration of 
two doses of daclizumab was compared with four months of corticosteroid treatment in 364 
renal transplant recipients on a tacrolimus and mycophenolate mofetil-based 
immunosuppressive regimen. We could demonstrate that treatment with two doses of 
daclizumab enabled the use of a steroid-free immunosuppressive regimen after renal 
transplantation (chapter six). There was no difference in the incidence of biopsy-proven acute 
rejection. The steroid-free immunosuppressive regimen had a temporary beneficial effect on 
several cardiovascular risk factors (lower blood pressure, lower serum cholesterol, and less 
new-onset diabetes mellitus). This beneficial effect should be balanced against the increased 
costs associated with the steroid-free regimen. 
In chapter seven, we describe that the steroid-free regimen as well as the regimen with limited 
steroid exposure prevented accelerated bone loss in the first year after transplantation. Four 
months of corticosteroid therapy had no important influence on the change in bone mass 
during the first year after renal transplantation.  
 
A low bone mineral density explains the increased fracture incidence in renal transplant 
recipients to a minor extent. The microarchitecture and the elasticity of bone are important 
factors involved in the strength of the bones. Dual energy X-ray absorptiometry, the standard 
method for the assessment of bone mineral density does not assess the structure of bone. 
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Quantitative ultrasound of bone has been shown to measure bone structure besides bone 
mineral density. In a sub-population of the earlier mentioned prospective randomized study 
we have compared these methods. We noted that four months of corticosteroid therapy did 
not influence quantitative ultrasound parameters of the calcaneus (chapter eight). However, 
quantitative ultrasound of bone seemed to measure different properties of bone compared with 
dual energy X-ray absorptiometry. While bone mineral density remained stable or improved 
between three and twelve months after transplantation, the quantitative ultrasound parameter 
broadband ultrasound attenuation continued to decrease in this period. The changes in the 
quantitative ultrasound parameter broadband ultrasound attenuation seem to reflect a 
continuing change in bone structure in this population with preexistent renal osteodystrophy.
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Na transplantatie van een orgaan van een niet-identieke donor, zal het afweersysteem van de 
ontvanger van dit orgaan een reactie in gang zetten om dit orgaan af te stoten. Om afstoting te 
voorkomen moet deze natuurlijke afweerreactie met medicijnen worden onderdrukt. Ongeveer 
20 jaar geleden was acute afstoting een belangrijke oorzaak van vroegtijdig verlies van het 
niertransplantaat. Destijds werden de patiënten behandeld met de weerstandverlagende 
medicijnen azathioprine en prednison. Eén jaar na de transplantatie functioneerde de nier maar 
bij 60-65% van de patiënten. Met de toepassing van nieuwe en krachtige medicijnen als 
ciclosporine, tacrolimus en mycofenolaat mofetil zijn de resultaten van niertransplantatie sterk 
verbeterd. Met een combinatie van deze medicijnen (tot nu toe altijd met prednison) heeft 
minder dan 25% van de patiënten een acute afstotingsreactie, en één jaar na de transplantatie 
functioneert de nier bij 80 tot 100% van de patiënten. Echter, veel patiënten met een 
niertransplantaat hebben bijwerkingen van deze medicijnen. Door langdurig gebruik van de 
weerstandverlagende medicijnen hebben deze patiënten een grotere kans op het krijgen van 
hart- en vaatziekten, ontstekingen, kwaadaardige ziekten en botbreuken. In ons streven om het 
afweersysteem optimaal te onderdrukken moeten we de voordelen van deze medicijnen 
(minder afstotingsreacties) afwegen tegenover de bijwerkingen. Recent zijn 
weerstandverlagende medicijnen beschikbaar gekomen, die op zeer specifiek wijze de afweer 
onderdrukken zonder duidelijke bijwerkingen. Voorbeelden hiervan zijn de monoklonale 
antistoffen basiliximab en daclizumab, welke de interleukine-2 receptor op de afweercellen 
blokkeren. Deze antistoffen worden altijd in combinatie met andere weerstandverlagende 
medicijnen gebruikt. In dit proefschrift beschrijven we onze ervaringen met daclizumab. Met 
name waren wij geïnteresseerd of het mogelijk is om daclizumab in de plaats van prednison te 
gebruiken na niertransplantatie. 
 
In hoofdstuk twee van dit proefschrift, wordt een overzicht gegeven van het gebruik van de 
interleukine-2 receptor blokkerende antistoffen na niertransplantatie. Tot nu toe werd 
daclizumab in vijf doses gegeven met een infuus. Theoretisch gezien lijkt een vermindering 
van het aantal doses geen invloed te hebben op de effectiviteit van daclizumab. Derhalve 
hebben wij besloten om de dosering daclizumab te verminderen tot twee doses na 
niertransplantatie. Om te weten of daclizumab na behandeling nog in het bloed van de patiënt 
aanwezig is, kan worden gemeten of de interleukine-2 receptor op de afweercellen geblokkeerd 
is. In hoofdstuk drie beschrijven wij, dat na de behandeling met twee infusen daclizumab de 
interleukine-2 receptor op de afweercellen meer dan 10 weken na de transplantatie geblokkeerd 
blijft. Daclizumab werd samen met twee andere weerstandverlagende medicijnen (tacrolimus 
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en mycofenolaat mofetil) gegeven. Met deze combinatie medicijnen had slechts 13% van de 
patiënten een acute afstoting.  
 
De standaardmethode om vast te stellen of de interleukine-2 receptor op de afweercellen is 
geblokkeerd, is technisch ingewikkeld en kost veel tijd. Wij hebben een alternatief voor deze 
standaardmethode ontwikkeld. Hiervoor hebben we de invloed van daclizumab op oplosbaar 
interleukine-2 receptor in het bloed onderzocht. Oplosbaar interleukine-2 receptor wordt 
normaal door de nier uit het bloed gefilterd en met de urine uitgescheiden. Het blijkt, dat 
daclizumab samen met oplosbaar interleukine-2 receptor een complex vormt, dat te groot is 
om gefilterd te worden door de nier (hoofdstuk vier). Zolang daclizumab in een voldoende 
hoge concentratie in het bloed aanwezig is, wordt oplosbaar interleukine-2 receptor niet met 
de urine uitgescheiden. Met het dalen van de concentratie van daclizumab in het bloed, wordt 
oplosbaar interleukine-2 receptor weer in de urine gevonden. Het meten van oplosbaar 
interleukine-2 receptor in de urine geeft dus informatie over de aanwezigheid van daclizumab 
in het bloed. In hoofdstuk vijf beschrijven wij, dat het meten van oplosbaar interleukine-2 
receptor in de urine een betrouwbare manier is om vast te stellen of de interleukine-2 receptor 
op de afweercellen geblokkeerd is na behandeling met daclizumab. Deze methode is 
eenvoudiger dan de standaardmethode om dit vast te stellen, en mogelijk zelfs iets beter. 
 
In hoofdstuk zes beschrijven we ons onderzoek waaruit blijkt dat het mogelijk is om 
daclizumab in plaats van prednison na niertransplantatie te geven. Dit onderzoek vond plaats 
bij 364 patiënten die een niertransplantatie ondergingen in de academische ziekenhuizen van 
Nijmegen, Rotterdam, Utrecht of Maastricht. Er werd voor de transplantatie geloot, waarbij 
de ene helft van de patiënten twee infusen met daclizumab kreeg, en de andere helft 
gedurende vier maanden prednison. Alle patiënten kregen eveneens de weerstandverlagende 
medicijnen tacrolimus en mycophenolate mofetil. Patiënten die behandeld werden met 
daclizumab hadden even vaak een afstotingsreactie als patiënten die behandeld werden met 
prednison. Patiënten die behandeld werden met daclizumab hadden tijdelijk een lagere 
bloeddruk, een lager cholesterol en een kleinere kans om suikerziekte te krijgen. De 
behandeling met daclizumab was echter duidelijk duurder dan de behandeling met prednison. 
In hoofdstuk zeven, beschrijven we dat de botdichtheid, gemiddeld genomen, in beide groepen 
niet veranderde. Behandeling met een matige dosis prednison gedurende vier maanden gaf 
geen duidelijke toename van botontkalking in het eerste jaar na niertransplantatie.  
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Bekend is dat patienten met een lage botdichtheid (osteoporose) eerder hun botten breken. 
Niet alle patiënten met een lage botdichtheid echter breken hun botten, en er zijn patiënten 
met een hoge botdichtheid die juist wel hun botten breken. Behalve de botdichtheid, zijn 
andere factoren zoals de structuur en de elasticiteit van het bot van belang voor de sterkte van 
het bot. Bekend is bij patiënten met een gestoorde nierfunctie, dat de structuur van het bot 
verandert. Met de standaardmethode voor het bepalen van de botdichtheid wordt geen 
rekening gehouden met veranderingen in de structuur van het bot. Kwantitative echo van het 
bot lijkt zowel de veranderingen in de structuur als de botdichtheid te meten. Bij 119 
patiënten hebben we gelijktijdig met de standaardmethode om de botdichtheid vast te stellen 
een botecho gedaan. In hoofdstuk acht beschrijven we dat behandeling gedurende vier 
maanden met prednison ook geen duidelijke invloed had op de uitkomst van de botecho 
metingen van het hielbeen. Echter, de botecho lijkt wel iets anders te meten dan de 
standaardmethode voor het bepalen van de botdichtheid. Terwijl de botdichtheid stabiel bleef 
of zelfs verbeterde tussen drie en twaalf maanden na transplantatie, nam de uitkomst van de 
botecho metingen alleen maar verder af in deze periode. Dit verschil met de 
standaardmethode is een aanwijzing, dat de botecho veranderingen in de botstructuur na 
niertransplantatie meet.  
 
Conclusie 
Met de huidige weerstandverlagende medicijnen heeft het merendeel van de patiënten één jaar 
na niertransplantatie een goede nierfunctie. Bijwerkingen van de weerstandverlagende 
medicijnen zijn voor veel patiënten een belangrijk probleem. De onderzoeken beschreven in dit 
proefschrift geven aan dat een beperkte dosis met de interleukine-2 receptor blokkerende 
antistof daclizumab, het mogelijk maakt om veilig zonder prednison een niertransplantatie te 
ondergaan. In vergelijking met de behandeling met een lage dosering prednison gedurende vier 
maanden is het voordeel van deze prednisonloze behandeling echter beperkt. De prednisonloze 
behandeling leidt tot een tijdelijke vermindering in een aantal risicofactoren voor hart- en 
vaatziekten, maar is tevens veel duurder dan het geven van prednison gedurende vier maanden. 
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In the last decades the results of renal transplantation have improved (1), at least partially as 
the result of the use of new and powerful immunosuppressive agents. Monoclonal antibodies 
against the alpha chain of the interleukin-2 receptor (IL-2Rα) are a new class of 
immunosuppressive agents with a highly specific mode of action. Two preparations are 
available for use, basiliximab and daclizumab, a chimeric and a humanized antibody, 
respectively. The first clinical studies have demonstrated the efficacy of these agents in 
reducing the rate of acute rejection. Most remarkably, the use of these agents was not 
associated with an increase in adverse events. Therefore it was hoped that these agents might 
prove an advantage in the management of renal allograft recipients. In our studies we have 
used daclizumab. In the present chapter we discuss the results of our studies in the context of 
our current knowledge on immunosuppressive treatment after renal transplantation. In general, 
studies have analyzed the benefits of anti-IL-2Rα therapy either added to standard 
immunosuppressive regimens (additional immunosuppression) or as replacement of one or 
more components of the standard immunosuppressive therapy (minimization of side effects). 
With respect to the side effects, we specifically discuss our experience with bone loss after 
transplantation. 
 
Use of anti-IL-2Rα therapy as additional immunosuppression 
Acute rejection 
Anti-IL-2Rα therapy has been demonstrated to decrease the acute rejection rate by ± 40 to 60% 
when added to cyclosporine combined with prednisone (2-4), and azathioprine (5;6), or 
tacrolimus, mycophenolate mofetil (MMF), and prednisone (7). In an underpowered trial, a 
tendency towards a decreased incidence of acute rejection was found after addition of 
basiliximab to cyclosporine, MMF and prednisone (8). There are no controlled studies that 
have evaluated the benefits of anti-IL-2Rα therapy when added to sirolimus-based 
immunosuppressive regimens.  
 
Long-term graft survival 
In the individual controlled trials, the one-year graft survival was not improved by induction 
therapy with anti-IL-2Rα antibodies (9). A study that combined the long-term follow-up data 
of two pivotal trials with daclizumab concluded that the graft survival at three year after 
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transplantation was also not better in the daclizumab-treated groups (10). Thus, at present 
there is no evidence that the forty percent decrease in the acute rejection rate after induction 
therapy with daclizumab translates in an improvement of long-term graft survival. Although 
there are no data, it is highly unlikely that conclusions will be different for induction therapy 
with basiliximab. This lack of a beneficial effect on graft survival challenges the view that it 
is worthwhile to increase the immunosuppressive load with anti-IL-2Rα therapy. Admittedly, 
longer follow-up might be required to detect a (small) survival advantage with anti-IL-2Rα 
therapy. 
 
Adverse events 
In the first studies anti-IL-2Rα therapy was very well tolerated (7;9). There was no increase in 
the number of adverse events. The data of the long-term follow-up study were also reassuring, 
with no increased risk to develop malignancies or infections in the daclizumab group (10). 
However, anaphylactic reactions have been described after (repeated) treatment with the 
chimeric antibody basiliximab (11-14). Three possible cases of hypersensitivity reactions 
have also been reported in patients using daclizumab (15). Close monitoring is required to 
detect less frequently occurring side effects that may become apparent only when anti-IL-2Rα 
therapy is used in a larger population. 
 
Limited dose regimen  
In the pivotal studies daclizumab was used in a five-dose regimen. In our studies we have 
administered daclizumab in a two-dose regimen with apparent success (rejection rate ±15%). 
Others have shown that even one dose of daclizumab decreased the acute rejection rate by ± 
60% (7). Therefore it seems feasible to limit the dose of daclizumab, which increases the 
easiness of administration and probably also the cost-effectiveness of this agent. We must 
admit that there are no controlled studies directly comparing the efficacy of different dose-
regimens in renal transplantation. Such a comparison has only been performed after 
simultaneous kidney-pancreas transplantation (16). In the latter study, no difference in acute 
rejection rate was found between a two and five-dose regimen (16).  
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Use of anti-IL-2Rα therapy to minimize side effects 
The lack of toxicity of anti-IL-2Rα therapy has been the rationale to develop 
immunosuppressive regimens in which anti-IL-2Rα therapy are used to replace other, more 
toxic immunosuppressive drugs. It is obvious, that the efficacy of such regimens must be 
determined in randomized controlled clinical studies. 
  
Comparison of anti-IL-2Rα therapy with antilymphocyte therapy 
Both polyclonal and monoclonal antilymphocyte antibodies are effective in delaying or 
preventing the onset of acute rejection. These agents even seem to prolong long-term graft 
survival in presensitized patients (17). However, the benefits of antilymphocyte therapy remain 
controversial. Moreover, antilymphocyte therapy is poorly tolerated due to the cytokine-release 
syndrome (18), and is clearly associated with an increased incidence of opportunistic infections 
and lymphoproliferative disease (19). A recent study revealed that antilymphocyte therapy is 
associated with an increased risk of death due to cardiovascular diseases, infections, and 
malignancies (20). Therefore, prophylactic use of antilymphocyte therapy is commonly 
restricted to patients at high immunological risk for rejection. Two small controlled studies in 
renal allograft recipients have compared anti-IL-2Rα therapy with antithymocyte globulin 
(21;22). In these studies, basiliximab and early initiation of cyclosporine was compared with 
antithymocyte globulin and initiation of cyclosporine after establishment of renal function. All 
patients additionally received MMF and prednisone. In both studies, the incidence of acute 
rejection was comparable in the two groups. One retrospective study has evaluated the effects 
of daclizumab and OKT3 induction therapy in patients treated with tacrolimus, MMF and 
prednisone. The acute rejection incidence was significantly lower (2%) in the daclizumab 
group compared with the OKT3 group (7%) (23). In all studies, adverse events (i.e. infections) 
were more frequently reported in antilymphocyte therapy treated patients. These data suggest 
that anti-IL-2Rα therapy may be preferable to antilymphocyte therapy for rejection prevention. 
Of note, the mentioned studies were not restricted to patients at high immunological risk.  
 
Comparison of anti-IL-2Rα therapy with MMF 
MMF has been shown to decrease the acute rejection rate by ± 50% when added to a 
cyclosporine-based regimen (24). In contrast to anti-IL-2Rα therapy, use of MMF has been 
shown to maintain long-term allograft function after renal transplantation (25;26). This long-
term effect was achieved by continuation of MMF for at least one year after transplantation. 
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Well-known adverse events of the use of MMF are gastrointestinal intolerance (27), bone 
marrow depression, and an increased susceptibility to symptomatic CMV infection (28). 
Replacement of MMF by anti-IL-2Rα therapy would avoid these adverse events, thus 
improving the quality of life in a proportion of the patients. However, there are no studies 
comparing anti-IL-2Rα (induction) therapy with (continuous) treatment with MMF.  
 
Comparison of anti-IL-2Rα therapy with calcineurin inhibitors 
The use of the calcineurin inhibitors cyclosporine (29) and tacrolimus (30) has significantly 
improved the results of organ transplantation. However, both calcineurin inhibitors frequently 
cause side effects, some acutely, others apparent after more chronic use only. Acutely these 
drugs can cause afferent arteriolar vasoconstriction leading to a reversible dysfunction of the 
renal allograft. Chronic administration of calcineurin inhibitors may cause interstitial fibrosis 
leading to an irreversible dysfunction of the renal graft (31;32). Both drugs increase 
cardiovascular risk factors such as hypertension, hyperlipidemia, and hyperglycemia, an 
important issue in view of the increased cardiovascular morbidity and mortality in this 
population (33). Withdrawal of cyclosporine has been shown to improve renal graft function 
and cardiovascular risk factors (34-37). In a meta-analysis, cyclosporine withdrawal was 
associated with an increase in acute rejection rates, although short-term graft survival was not 
impaired (38).  
Avoidance of calcineurin inhibitors after transplantation has been the focus of several studies. 
In phase II studies, induction therapy with daclizumab in combination with MMF and 
prednisone (39;40) resulted in an acute rejection rate of 38% and 50%. This rejection rate is 
disproportional high, when compared to studies using a calcineurin inhibitor in combination 
with MMF and prednisone. It is therefore evident, that anti-IL-2Rα therapy is less effective 
than a calcineurin inhibitor to prevent acute rejection episodes. Graft survival however was 
excellent in these studies, and long-term follow-up data have to be awaited.  
In a small randomized study, the acute rejection rate was 16% in patients treated with a 
combination of basiliximab, sirolimus, MMF and prednisone, comparable to the 6% rejection 
rate in patients treated with a combination of cyclosporine, MMF and prednisone (41). Other 
(small) studies have compared sirolimus- and cyclosporine-based regimens, all without anti-
IL-2Rα therapy, and observed a comparable incidence of acute rejection with both regimens 
(42;43). These studies suggest that sirolimus is effective for prevention of acute rejection, and 
thus may replace the calcineurin inhibitors. However, as stated above, it is unclear if anti-IL-
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2Rα therapy is of additional value when added to treatment with sirolimus after 
transplantation.   
Avoidance of calcineurin inhibitors is especially of interest in patients with a kidney from a 
marginal donor. These patients are particularly susceptible to the acute hemodynamic side 
effects of the calcineurin inhibitors, leading to a delayed function of the allograft. 
Uncontrolled observations have suggested that anti-IL-2Rα therapy (44) combined with 
sirolimus (45) may delay or even avoid (46) the use of calcineurin inhibitors. Promising 
results were also obtained after conversion from a calcineurin inhibitor-based regimen to a 
sirolimus-based regimen combined with anti-IL-2Rα therapy in patients with hemolytic 
uremic syndrome after transplantation (47). However, treatment with sirolimus has also been 
associated with an increase in delayed graft function (48;49), so controlled trials specifically 
evaluating possible advantages of sirolimus in patients with delayed graft function or a 
hemolytic uremic syndrome are needed.  
 
Comparison of anti-IL-2Rα therapy with corticosteroids 
Corticosteroid therapy has been the mainstay for rejection prophylaxis after transplantation. 
The use of corticosteroids is associated with several well-documented side effects such as 
hypertension, hyperlipidemia, new-onset diabetes mellitus, infections, a cushingoid habitus, 
skin bruising, and accelerated bone loss (50). Many of these steroid-related side effects clearly 
improve after withdrawal of prednisone (51), but at the cost of an increased incidence in acute 
rejection (38). Certainly, in the short-term the risk of graft failure is low. However, concern 
has been raised by reports relating steroid-withdrawal with long-term allograft failure in 
patients on cyclosporine-based regimens (38). Newer more potent immunosuppressive drugs, 
such as tacrolimus (52) and MMF might overcome the problem of acute rejection after 
steroid-withdrawal. We have evaluated the efficacy of daclizumab as replacement therapy for 
steroids in renal allograft recipients treated with a combination of tacrolimus and MMF (53). 
All patients also received prednisolone intravenously for three days after transplantation. 
Control patients received corticosteroids for only four months after transplantation. The actual 
benefit of our steroid-free regimen was limited. Cardiovascular risk factors were temporary 
improved, but at twelve months after transplantation differences no longer existed between 
the two groups. Besides, the steroid-free regimen tended to increase the severity of the acute 
rejection episodes, had no important benefit on the rate of bone loss in the first year after 
transplantation, and was more expensive. Thus, the regimen used in our control group, 
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consisting of four months of corticosteroid therapy combined with tacrolimus and MMF 
seems a reasonable option to limit steroid-related side effects after transplantation. It remains 
to be determined if the steroid-related side effects can be further limited by avoiding the 
initial i.v. prednisolone bolus. Furthermore it has not been proven that the addition of anti-IL-
2Rα therapy is really necessary to achieve the results that were obtained with the steroid-free 
regimen. 
 
Alternative indications for anti-IL-2Rα therapy in renal transplantation 
Anti-rejection therapy 
Thus far anti-IL-2Rα therapy has been mainly applied as induction treatment for prevention 
of acute rejection. Several uncontrolled studies have claimed the usefulness of anti-IL-2Rα 
therapy in the treatment of acute rejection after organ transplantation. These studies however 
were confounded by the concomitant conversion of cyclosporine to tacrolimus (54), by the 
concomitant lowering of the dose of tacrolimus in a patient with tacrolimus toxicity (55), and 
by the absence of histological proof of the rejection episodes (56). Controlled studies have to 
be awaited to define the role of IL-2Rα antibodies in the treatment of acute rejection. 
 
Prevention of rejection after conversion of immunosuppressive regimen 
After successful transplantation the dose of immunosuppression can be gradually lowered. 
Many centers in fact try to reduce the intensity of immunosuppression. Well-known examples 
of such changes of immunosuppression are the conversion of cyclosporine and prednisone to 
azathioprine and prednisone. However, the replacement of cyclosporine by azathioprine 
results in the occurrence of an acute rejection in approximately 20% of the patients (37;38). It 
is unknown if anti-IL-2Rα therapy will reduce this rejection rate. In an uncontrolled study, 
daclizumab was given during the conversion from tacrolimus- to sirolimus-based 
immunosuppression (47). In this study only one of 27 patients (3%) experienced an acute 
rejection. However, in another study no rejection episodes occurred in 15 patients during 
conversion from tacrolimus- to sirolimus-based immunosuppression without additional anti-
IL-2Rα therapy (57). Controlled studies are needed to determine whether anti-IL-2Rα therapy 
can prevent rejection episodes during conversion of immunosuppressive regimens. 
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Monitoring of IL-2Rα therapy 
We have developed an alternative method for monitoring the presence of daclizumab in serum 
by measurement of the fractional excretion of soluble IL-2Rα (58;59). This method proved 
more sensitive than the current gold standard, flow cytometric measurement of IL-2Rα on 
peripheral lymphocytes. The clinical value of monitoring the level and duration of IL-2Rα 
blockade has still to be determined. While therapeutic drug monitoring is not necessary in 
patients treated with a standard dose of anti-IL-2Rα mAb (60), monitoring might be of value 
to determine the minimum dose of the (expensive) IL-2Rα blocking monoclonal antibodies 
required for effective rejection prophylaxis. Furthermore, monitoring might become relevant 
if alternative treatment protocols using anti-IL-2Rα therapy are developed i.e. prolonged 
treatment in patients with severe toxicity of standard immunosuppressive drugs.  
 
Prevention of (steroid-related) bone loss 
Renal allograft recipients are at increased risk to develop bone fractures after transplantation 
(61). Loss of bone mass after transplantation has been attributed to the use of steroids. 
Therefore, we have used a nearly steroid-free regimen consisting of daclizumab, tacrolimus, 
and MMF. Although we cannot exclude that bone loss is attenuated by this regimen, the 
benefits compared to the control regimen, which only included 4 months of prednisone 
treatment, were limited (62). However, it is important to note, that bone loss in our control 
patients was almost negligible, making it very difficult to demonstrate a beneficial effect. In 
the past years we have regularly measured bone loss in our transplant patients. If we compare 
bone loss in the various patient cohorts, it becomes obvious that there is a clear relation 
between loss of bone mass and steroid dose (Figure 1). Furthermore in a controlled trial we 
have demonstrated that treatment with active vitamin D and calcium attenuates bone loss (63). 
Other investigators have demonstrated a comparable benefit using biphosphonates (64;65). 
Thus, there are several treatment options for patients at high risk for bone fractures: choose a 
regimen with the lowest possible dose of steroids; add active vitamin D and calcium or 
bisphosphonates. Future studies have to determine whether prophylactic treatment with 
vitamin D or bisphosphonates is of additional value in renal allograft recipients treated with 
such a low dose of steroids. 
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Figure 1. The relation between the use of corticosteroids, and the changes in bone mineral 
density during the first year after transplantation in studies performed at our center (62;63;66). 
The median cumulative steroid dose of each group is presented at the end of each line. In one 
study group additional treatment with vitamin D was given. (black versus open squares: steroid-
free regimen versus 4 months steroids (62); closed versus open triangles: Vitamin D and calcium 
prophylaxis versus no prophylaxis (63); closed circles (66)). 
chapter 11   
 140
Future perspectives 
The ideal solution to prevent immunologic destruction of organ allografts would be to make 
recipients of a allograft tolerant to donor tissues. After induction of tolerance no 
immunosuppressive drugs are needed for preservation of allograft function. The role of anti-IL-
2Rα therapy in tolerance induction protocols is controversial. For optimal allograft acceptance, 
allograft-specific recognition and activation of T-cells should occur, leading to the eventual 
apoptosis of the alloreactive cells. Several experiments indicate that therapies that target the 
IL-2 pathway such as anti-IL-2Rα therapy and calcineurin inhibitors, prevent the induction of 
allograft acceptance by hindering apoptosis of these alloreactive cells (67-69).  
The most exciting development in induction of (partial) tolerance in human renal 
transplantation has been reported by the groups of Calne (70) and Startzl (71). In their 
uncontrolled studies, tolerance to the allograft was induced by a regimen consisting of a pan T-
cell depleting antibody followed by a (very) low dose of a calcineurin inhibitor. Steroids were 
only given before transplantation to prevent cytokine-release that follows the infusion of 
antilymphocyte antibodies. Graft and patient survival were excellent. Interstitial infiltrates, 
suggestive for acute rejection were frequently seen in protocol biopsies, but in the absence of 
graft dysfunction, the authors did not consider these infiltrates as harmful, but as a stage in the 
evolution of immunological tolerance. Immunosuppression related morbidity was virtually 
eliminated with these regimens. Although very promising, controlled studies have to be 
awaited before implementation can be advised. 
Another promising area of research is the development of tools to measure the immunological 
status of the renal allograft recipients. In pilot studies it was shown that the absence of donor-
specific cytotoxic T-lymphocytes predicted the successful withdrawal of immunosuppression 
(72). We must await further development and implementation of these techniques after renal 
transplantation. With these tools, the degree of immunosuppression can be modified to the 
individual needs required for optimal rejection prophylaxis. 
  
Conclusion 
One-year graft survival is excellent with currently available immunosuppressive drugs. Anti-
IL-2Rα therapy decreases the acute rejection rate when added to a calcineurin inhibitor-based 
immunosuppressive regimen. However, augmenting the immunosuppression with the highly 
selective acting IL-2Rα antibodies did not improve three-year graft survival. The lack of 
toxicity of anti-IL-2Rα therapy has been the rationale to replace other, more toxic 
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immunosuppressive drugs by anti-IL-2Rα therapy. Replacement of corticosteroids after 
transplantation by administration of the IL-2Rα antibody daclizumab is feasible. However, 
the benefit of this expensive regimen is limited compared with a regimen with limited steroid 
exposure. Anti-IL-2Rα therapy is not efficacious enough to replace the continuous use of a 
calcineurin inhibitor after renal transplantation. Sirolimus on the other hand, seems 
efficacious enough to replace the continuous use of calcineurin inhibitor. It is unclear whether 
anti-IL-2Rα therapy is of additional value to a sirolimus-based immunosuppressive regimen. 
Considering the excellent one-year graft survival achieved with the current 
immunosuppressive regimens, long-term follow-up is required to detect potential benefits of 
these newly developed regimens. 
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van Isselt en Alice van Dongen (UMC Utrecht) en  Lia van Iersel (UMC Maastricht). 
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dank ik voor het overleg over de botecho’s. 
De (oud-) collegae van de afdeling nierziekten van het UMC St Radboud, dank ik voor de 
plezierige samenwerking van de afgelopen jaren. Ik reken op een voortzetting van deze 
samenwerking vanuit het Canisius Wilhelmina Ziekenhuis. 
Reinout van Crevel en Alfons den Broeder dank ik voor de gezamenlijke racefiets en 
hardloop activiteiten, en misschien nog meer voor de sterke verhalen ervoor en erna. Ik dank 
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vriendschap en pogingen het kokerkijken van de aanstaande promovendus te beperken heb ik 
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Mijn ouders en schoonouders, allen dank ik voor hun steun en persoonlijke bijdrage. Mijn 
drie kinderen Daan, Jaap en Margot dank ik voor hun altijd en alles relativerende 
aanwezigheid. Lieve Akosua, zonder jou zou ik waarschijnlijk niet gepromoveerd zijn. Kort 
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